



UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

4301 JONES BRIDGE ROAD
BETHESDA, MARYLAND 20814-4799



GRADUATE EDUCATION
(301) 295-3913
FAX (301) 295-6772

APPROVAL SHEET

Title of Dissertation: "The Regulation of Endogenous Glutamate and GABA Release from *In Vitro* Preparations of Rat Striatum"

Name of Candidate: James B. Phillips, Jr.
Doctor of Philosophy Degree
19 September 1997

Dissertation and Abstract Approved:

Thomas Cote, Ph.D.
Department of Pharmacology
Committee Chairperson

9-29-97

Date

Brian Cox, Ph.D.
Department of Pharmacology
Committee Member

9/29/97

Date

Cinda Helke, Ph.D.
Department of Pharmacology
Committee Member

9/19/97

Date

Joseph Long, Ph.D.
Department of Pharmacology
Committee Member

19 Sept 97

Date

MAJ Ajay Verma, MC, USA
Department of Neurology
Committee Member

9/19/97

Date



Report Documentation Page

*Form Approved
OMB No. 0704-0188*

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

1. REPORT DATE 1997	2. REPORT TYPE	3. DATES COVERED -
4. TITLE AND SUBTITLE The Regulation of Endogenous Glutamate and Gaba Release from In Vitro Preparations of Rat Striatum		
5a. CONTRACT NUMBER		
5b. GRANT NUMBER		
5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S)		
5d. PROJECT NUMBER		
5e. TASK NUMBER		
5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Uniformed Services University of the Health Services,F. Edward Herbert School of Medicine,4301 Jones Bridge Road,Bethesda,MD,20814-4799		
8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)		
10. SPONSOR/MONITOR'S ACRONYM(S)		
11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited		
13. SUPPLEMENTARY NOTES		
14. ABSTRACT see report		
15. SUBJECT TERMS		
16. SECURITY CLASSIFICATION OF:		
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified
17. LIMITATION OF ABSTRACT		18. NUMBER OF PAGES 104
		19a. NAME OF RESPONSIBLE PERSON

The author hereby certifies that the use of any copyrighted material in the thesis manuscript entitled:

"The Regulation of Endogenous Glutamate and GABA Release from *In Vitro* Preparations of Rat Striatum"

beyond brief excerpts is with the permission of the copyright owner, and will save and hold harmless the Uniformed Services University of the Health Sciences from any damage which may arise from such copyright violations.



James B. Phillips, Jr.
Department of Pharmacology
Uniformed Services University of the Health Sciences

ABSTRACT

The release of the major excitatory and inhibitory neurotransmitters, glutamate and GABA, from rat caudate-putamen (CP) tissue slices, and GABA release from fetal rat primary striatal cultures, were studied to ascertain key mechanisms underlying the regulation of their release. An improved, highly sensitive method of high performance liquid chromatography and electrochemical detection (LCED) was developed to enable the reliable measurement of these endogenous amino acids from tissue release extracts. The assay permits detection of endogenous amino acids from one milligram of CP tissue *in vitro*. Release of both amino acids from CP tissue was evoked by elevated levels of potassium, while the potassium channel blocker, 4-aminopyridine (4-AP), selectively released GABA. Glu was selectively released by the excitatory amino acid (EAA) receptor agonist, N-methyl-D-aspartate (NMDA), independently of external Ca^{2+} concentration. Ca^{2+} -dependent release of Glu and GABA by potassium- and 4-AP-evoked depolarization was shown to be solely dependent on external Ca^{2+} influx through the P-type Ca^{2+} channel ($P<0.005$); blockade of L- and N- types of Ca^{2+} channels did not reduce release of either amino acid. Potassium and 4-AP also evoked Ca^{2+} -dependent release of GABA from the striatal cultures; GABA was also released by Glu, through a Ca^{2+} -independent process. Activation of D_1 dopamine receptors elicited a significant stimulation of GABA release from striatal cultures ($P<0.01$), but no dopaminergic effects were observed on release of either amino acid in CP tissue slices. Potassium (50 mM KCl) stimulated release of GABA from the cultures was shown to be significantly increased by bicuculline ($P<0.05$), the GABA_A receptor antagonist.

These studies suggest that NMDA or Glu stimulation of *in vitro* Glu and GABA release is most likely mediated through depolarization-evoked reversal of the plasma membrane amino acid transporters. Dopamine has a facilitatory influence on striatal GABA release, and autoreceptor regulation of GABA release is through the GABA_A

receptor. The experimental conditions under which Glu and GABA were analyzed, provide an efficient means of studying regulatory influences of striatal amino acid release.

THE REGULATION OF ENDOGENOUS GLUTAMATE AND GABA RELEASE
FROM *IN VITRO* PREPARATIONS OF RAT STRIATUM

by

James B. Phillips, Jr.

Dissertation submitted to the Faculty Committee from Departments of
Pharmacology and Neurology and the Neuroscience Program of the Uniformed
Services University of the Health Sciences in partial fulfillment of the
requirements for the degree of Doctor of Philosophy
1997

Dedication

To my wonderful and loving wife, Rebecca Rohrer.

Acknowledgments

Thanks Rebecca for your continued support and encouragement.

I would like to acknowledge my mentor, Dr. Brian Cox. I will value his guidance and advice throughout my scientific career.

I would like to thank the additional members of my dissertation committee, Drs. Tom Cote, Cinda Helke, Joe Long and Ajay Verma. I greatly appreciate their individual attention devoted to the successful completion of my graduate degree.

Special appreciation is extended to Dr. Cote for serving as chairman of my committee. His enthusiasm was an inspiration throughout my tenure at USUHS.

Additional thanks to Dr. Helke for her keen scientific and professional advice.

I would like to especially recognize my parents - I greatly appreciate their support and inspiring me to pursue my dreams.

Table of Contents

List of tables	x
List of figures	x
Abbreviations	xii
INTRODUCTION	1
Nuclear subdivision of the basal ganglia	1
Dorsal (nonlimbic) basal ganglia	1
Ventral (limbic) basal ganglia.....	2
Major neurons and neurotransmitters of the basal ganglia	3
GABA	4
Glutamate	6
Dopamine	7
Acetylcholine	8
Opiate peptides.....	9
Serotonin	11
Substance P	12
Metabolic relationship of glutamate and GABA in the CNS.....	14
Pharmacological significance of the glutamatergic and GABAergic synapse in the striatum.....	15
Stimulators of neurotransmitter release	18
Specific calcium channels involved in axonal and dendritic neurotransmitter release.....	19
Dopamine and opiate interactions in primary cultures of striatal neurons	21
HPLC analysis of amino acids in biological tissue.....	22
Basic hypothesis and specific objectives	24
METHODS	25
Assay for glutamate and GABA release from rat caudate-putamen tissue slices	25
Fetal rat primary striatal cultures	26
Assay for GABA release from fetal rat primary striatal cultures.....	28
Measurement of glutamate and GABA through HPLC analysis	28
Statistical analysis	30
RESULTS	31
Development of a sensitive HPLC assay to reliably measure glutamate and GABA release	31

Table of Contents continued

Internal standard selection	31
Baseline elution of glutamate and GABA.....	32
Effect of mobile phase pH on amino acid separation and elution	35
Characterization of the sources of released glutamate and GABA from rat caudate-putamen tissue slices	38
Depolarizing stimuli in the release of glutamate and GABA	38
Effects of specific reuptake inhibitors on glutamate and GABA release	42
Effects of specific Ca^{2+} channel blockers on glutamate and GABA release	46
Local transmitter influence on the release of glutamate and GABA from rat caudate-putamen tissue slices	49
Endogenous GABA release from fetal rat primary striatal cultures	54
Release of GABA by depolarizing stimuli	54
Dopamine receptor activity on basal and stimulated release of GABA	57
μ -Opiate receptor activity on stimulated release of GABA	59
DISCUSSION	62
HPLC and electrochemical detection of glutamate and GABA	62
Release of glutamate and GABA from rat caudate-putamen tissue slices by depolarizing stimuli.....	65
Significance of presynaptic reuptake on potassium-evoked release of glutamate and GABA from rat caudate-putamen tissue slices	68
P-type calcium channel involvement in the calcium-dependent release of glutamate and GABA from rat caudate-putamen tissue slices	70
Local transmitter influence on amino acid release from rat caudate-putamen tissue slices through actions of specific receptor ligands	72
GABA release from fetal rat primary striatal cultures	74
CONCLUSIONS	79
REFERENCES.....	81

List of tables

Effects of specific Ca^{2+} channel blockers on potassium- and 4-AP- stimulated release of glutamate and GABA from rat CP tissue slices	48
The effects of local striatal receptor antagonism on potassium-stimulated release of glutamate and GABA from rat CP tissue slices.....	51
The effects of selective opiate receptor agonist on potassium-stimulated release of glutamate and GABA from rat CP tissue slices.....	52
Effects of D_1 DA receptor stimulation on basal and potassium-stimulated release of glutamate and GABA from rat CP tissue slices	53

List of figures

The basal ganglia loop	2
Projections of the striatal medium-sized GABAergic neurons	5
Dopaminergic innervation of the striatum	8
Opiate receptor localization within the striatum	11
Metabolic relationship of glutamate and GABA	14
OPA- SO_3 derivatization of glutamate and GABA	23
Chromatograms of the internal standards	32
Chromatograms of amino acid standards and the effects of excess electroactive sulphite	33
Standard curves for glutamate and GABA	34
Chromatograms showing the effect of eluant pH of amino acid separation	36
Effects of mobile phase pH on amino acid separation and elution	37
Dose response curves for potassium stimulated release of glutamate and GABA from rat CP tissue slices	39
4-AP and NMDA stimulated release of glutamate and GABA from rat CP tissue slices	41
Ca^{2+} -dependency of 4-AP stimulated release of GABA from rat CP tissue slices	42
Effect of nipecotic acid on potassium stimulated release of glutamate and GABA	43
Effect of L-trans-2,4-PDC on potassium stimulated release of glutamate and GABA	43

List of figures continued

Effect of nipecotic acid and L-trans-2,4-PDC on basal release of glutamate and GABA	44
Ca ²⁺ -dependency of nipecotic acid's effect on basal and stimulated release of GABA	45
AgTx IVa significantly reduces potassium-stimulated release of glutamate and GABA and 4-AP-stimulated release of GABA from rat CP tissue slices	47
Effects of atropine and saclofen on potassium-stimulated release of glutamate and GABA from rat CP tissue slices	50
Typical chromatograms of LCED analysis of the derivatized culture releasate	55
Release of GABA from primary striatal cultures by potassium, 4-AP and glutamate	56
Effect of D ₁ DA receptor stimulation on basal release of GABA from primary striatal cultures	57
D ₁ DA receptor antagonism blocks the D ₁ -receptor stimulation of GABA release from primary striatal cultures	58
Effect of GABA receptor antagonism on potassium-stimulated release of GABA from primary striatal cultures	60
Effect of μ -opiate receptor activation on the bicuculline-evoked increase in potassium-stimulated release of GABA	61
Ca ²⁺ -dependent and -independent release of GABA	75

Abbreviations of commonly used terms

4-AP	4-aminopyridine
5-HT	serotonin
ACh	acetylcholine
AgTx IVa	ω -agatoxin IVa
AMPA	α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid
ANOVA	analysis of variance
BG	basal ganglia
CnTx GVIA	ω -conotoxin GVIA
CP	caudate-putamen
DA	dopamine
DYN	dynorphin
EAA	excitatory amino acid
ENK	enkephalin
GABA	γ -aminobutyric acid
GABA-T	GABA transaminase
GAD	glutamic acid decarboxylase
Glu	glutamate
HPLC	high performance liquid chromatography
HRP	horse radish peroxidase
L-trans-2,4-PDC	L-trans-pyrollidine-2,4-dicarboxylic acid
LCED	liquid chromatography-electrochemical detection
LPS	lateral pallidal segment
MKB	modified Krebs-HEPES buffer
MPS	medial pallidal segment
NAcc	nucleus accumbens
NMDA	N-methyl-D-aspartate
OPA-SO ₃	o-phthalaldehyde-sodium sulphite
PBS	phosphate buffered saline
PSC	fetal rat primary striatal cultures
SEM	standard error of the mean
SN	substantia nigra
SNc	substantia nigra pars compacta
SNr	substantia nigra pars reticulata
SP	substance P

Abbreviations continued

STN	subthalamic nucleus
VP	ventral pallidum
VTA	ventral tegmental area

INTRODUCTION

A. Nuclear subdivision of the basal ganglia

The basal ganglia (BG) are a mass of subcortical nuclei arranged into multiple internal loops that use various neurotransmitters to communicate between subdivisions. The major divisions of the BG are the corpus striatum and the amygdaloid nuclear complex. The corpus striatum includes the caudate nucleus, the nucleus accumbens (NAcc), the putamen, and the globus pallidus. Together, the caudate, NAcc and putamen form the neostriatum and are collectively referred to as the striatum. The BG is also divided anatomically into dorsal and ventral aspects. The dorsal aspect of the BG primarily consists of the caudate, putamen and globus pallidus; they extend ventrally below the anterior commissure to form the ventral striatum and the ventral pallidum (Heimer et al., 1991). The ventral extensions of the corpus striatum and the amygdaloid nuclear complex form the ventral tier of the BG which is associated with limbic functions of the BG circuitry. The dorsal, non-limbic portion is primarily associated with motor activity. For clarity, within the context of this text, I will generally refer to the dorsal and ventral aspects of the striatum as the caudate-putamen (CP) and NAcc, respectively, and "striatum" refers to both dorsal and ventral neurons of the caudate, putamen and NAcc, collectively.

1. Dorsal (nonlimbic) basal ganglia

The most studied aspect of the BG circuitry is the dorsal region through its association with planning, initiation, and learning of motor movement. Muscle movement disorders such as Huntington's Chorea and Parkinson's Disease stem from abnormal connections between subdivisions and nuclei of the BG that normally form a circuit of information relayed by various neurotransmitter interactions (Albin et al., 1989). The anatomy of the dorsal BG is often referred to as a subcortical motor loop or extrapyramidal system which possesses a basic circuit superimposed within the output of the motor cortex (Graybiel, 1990; Cedarbaum and Schleifer, 1990; and Riederer et al., 1992).




FIGURE 1 - The basal ganglia loop showing both direct and indirect pathways (Adapted from Gross Anatomy III notes, Dept of Anatomy, USUHS).

In figure 1, this loop is shown along with the key nuclei involved in the normal flow of neuronal information. The loop receives a majority of its signals from the cortex, shuffles them through an inter-connected network of neurons and nuclei, then sends these cortical signals back to specific areas of the

cortex in a defined pattern to regulate motor memory and motor planning (Graybiel, 1990; and Graybiel et al., 1993).

The CP (and NAcc) is the primary receptive structure of the BG which receives the majority of its information from the substantia nigra pars compacta (SNc) and all major areas of the cortex (Kemp et al., 1970). The CP sends efferent projections to the primary output neurons of the BG, the medial pallidal segment (MPS) and the substantia nigra pars reticulata (SNr), through both direct and indirect pathways. The direct pathway sends inhibitory striatonigral and striatoendopeduncular projections, while the indirect pathway begins by sending inhibitory projections to the lateral pallidal segment (LPS). The LPS then projects inhibitory input to the subthalamic nucleus (STN), and the STN in turn sends stimulatory projections to the output nuclei of the BG. The two pathways allow for both an inhibitory input into the MPS and SNr through the direct route and a stimulatory input through the indirect pathway. Output from the dorsal BG, via the MPS and SNr, leads to the ventrolateral thalamic nucleus and then the primary motor cortex before the descending motor pathway is activated.

2. *Ventral (limbic) basal ganglia*

The three major areas of the ventral BG are the amygdala, the NAcc, and the ventral pallidum (VP). Together these structures, though function as an integral part of the limbic

system, do not form a distinct subcortical circuit loop like the dorsal BG as seen in Figure 1. The amygdala differs from other BG nuclei in that it sends efferents to numerous nuclei located outside the BG, while the MPS and SNr, the major output nuclei of the BG, send most of their fibers to the thalamus and superior colliculus. The amygdala efferents projecting beyond the BG extend to the thalamus, the hypothalamus, the septal area, the hippocampus, subiculum, substantia innominata, entorhinal cortex, the somatosensory cortex and constitute the stria terminalis. The amygdaloid nuclear complex also sends descending fibers to the parabrachial nuclei, the solitary fasciculus, and dorsal motor nucleus of the vagus (Carpenter, 1991). Within the BG, the amygdala projects to the ventral striatum, including the NAcc and the olfactory tubercle.

The principle efferent projections of the NAcc are GABAergic and extend primarily to the VP and mesencephalic regions including the ventral tegmental area (VTA). These projections are involved in two distinct reciprocal circuits. Accumbal projections to the VP and the VTA are reciprocated by pallidal GABAergic efferents and tegmental GABAergic and dopaminergic projections (Van Bockstaele and Pickel, 1995). These circuits serve as feedback loops whereby transmitter release within the ventral tier of the BG is under local control. Afferents of the NAcc arise primarily from the cortex, VP, amygdala, and VTA. The temporal, prefrontal, and parietal association cortices, as well as the amygdala projections are stimulatory. The VP is thought to project GABA, and the VTA sends stimulatory and inhibitory projections through GABA and dopamine (DA) neurons; the dopaminergic pathway is implicated in the reinforcing properties of abused drugs (Fuxe et al., 1985; Groenewegen et al., 1994; and Self and Nestler, 1995).

B. Major neurons and neurotransmitters of the basal ganglia

When considering the role that the BG play in the control over motor movement and relaying behavioral information, it seems likely that this subcortical mass of nuclei would have a remarkable number of neurotransmitters and receptors. Indeed, the BG circuitry is

rich in classical neurotransmitters such as DA, GABA, glutamate (Glu), acetylcholine (ACh) and serotonin (5-HT). Some of these transmitters are co-located with peptide neurotransmitters such as the opiates, substance P, somatostatin, cholecystokinin, vasoactive intestinal polypeptide, and neuropeptides (Guttman, 1987; and Semba et al., 1987). The transmitters arise from nerve terminals, interneurons and dendrites that are located throughout the BG. Because the striatum receives most of the BG input coming primarily from the cortex, thalamus, substantia nigra, and amygdala, it contains the most diverse amount of transmitters and receptors; while, the striatal efferent targets, the globus pallidus and substantia nigra, are less heavily innervated by different transmitters. The amygdala, being an integral part of the limbic system, also contains a great diversity of transmitters and receptors. Peptide transmitters are especially high, and the amount of somatostatin in the amygdala is among the highest in the brain (Carpenter, 1991). The transmitters discussed below will primarily focus on their interactions within the striatum, because the project centers on Glu and GABA release in this area, although the circuitry of the BG cannot be ignored.

1. GABA

The predominant neurotransmitter within the BG is GABA (Graybiel, 1990). It is estimated that over eighty percent of neurons in the NAcc and over ninety percent in the dorsal striatum use GABA as their neurotransmitter (Smith and Sharp, 1994b; and Maneuf et al., 1994), and most neurons of the globus pallidus and SNr are GABAergic (Graybiel, 1990). Most GABAergic neurons are medium-size, spiny type, while a few, specifically within the striatum, are medium-sized, aspiny interneurons (Fonnum et al., 1977). Retrograde transport of HRP with Golgi impregnation under electron microscopy has established that almost all projection neurons of the striatum are the medium-size spiny

type with dendrites densely covered with spines as shown in figure 2 (Smith and Bolam, 1990). In the striatum, GABA is located in two distinct classes of neurons; one containing GABA, substance P (SP), and dynorphin (DYN) which projects to the SNr and the medial pallidal segment and the other which contains GABA co-localized with enkephalin (ENK) and projects to the lateral pallidal segment (Maneuf et al., 1994)

(see figure 2). These two types of GABAergic neurons are laterally connected through recurrent collaterals arising from their striatal efferent medium spiny axons as indicated in figure 2 (Smith and Bolam, 1990). The GABA/SP/DYN cell bodies also project interneurons which act on cholinergic neurons within the CP (Di Chiara et al., 1994).

GABA is thought to be released by several means in the BG. In the GP and SN, GABA is released from the terminals of striatal axons, and is under presynaptic control by mainly autoinhibition. GABA release in the striatum is from terminals of recurrent collaterals, interneurons and proximal dendrites. Dendritic release is thought to exist because GABA release from striatal slices is tetrodotoxin resistant (Glowinski et al., 1994). Glowinski et al (1994) have shown that NMDA receptor activation can stimulate GABA release from collaterals and dendrites in the striatum, and Smith and Bolam (1990) have




FIGURE 2 - Medium spiny GABAergic neurons of the striatum and the basal ganglia loop. Adapted from Smith and Bolam, 1990.

shown that the dendrites of medium-size spiny GABA neurons are directly innervated with DA, Glu, ACh, and SP terminals.

2. *Glutamate*

Glutamate innervates the striatum through both corticostriatal and thalamostriatal fibers and innervates the SNr and GP through subthalamic efferent fibers. Anterograde tracing and immunocytochemistry have shown that Glu input into the striatum is fairly disperse throughout the caudate nucleus, putamen, and NAcc, but that synaptic contact is selective for specific neurons in the striatum. Glutamatergic fibers from the parafascicular nucleus of the thalamus make direct contact with intrinsic cholinergic neurons in both the dorsal and ventral striatum, while corticostriatal neurons presumably make contact with GABAergic output neurons of the striatum and DA neurons dispersed throughout the striatum (Meredith and Wouterlood, 1990; and Lapper and Bolam, 1992). Glu fibers from the STN which innervate the output nuclei of the BG is part of the indirect pathway of the BG circuitry. The STN also acts back on the LPS and is thought to function as a feedback mechanism (Smith et al., 1994). Smith and Parent (1988) have shown that the majority of subthalamic efferent fibers are glutamatergic that act on the SNr and GP and are themselves innervated by GABAergic afferents of the LPS.

Through AMPA and NMDA receptors Glu mediates excitatory activity on most neurons of the striatum. The activated AMPA receptor mediates a fast stimulatory response, and the NMDA response is considered slower and referred to as 'modulatory' (Di Chiara et al., 1994). The NMDA receptor is a voltage-gated ion channel that is under a Mg^{2+} blockade; it requires a depolarization of the neuron to overcome the block. Therefore, Glu neurons innervating the striatum require AMPA receptors or excitatory cholinergic and dopaminergic input to depolarize the neuron and relieve the Mg^{2+} block (Di Chiara et al., 1994). DA afferents converge with Glu terminals on dendritic spines of GABA neurons to yield a combined influence on GABA release (Cepeda et al., 1993; and Kötter, 1994), although they do not necessarily produce a synergistic effect. Cepeda et al

(1993) showed that D₁ DA receptor stimulation enhances NMDA receptor responses, while D₂ DA receptors inhibit both NMDA and AMPA receptor increases in electrical potential in rat neostriatal slices.

3. Dopamine

Dopamine innervates the striatum from the retrorubral nucleus, the SNc, and the VTA (cell groups A8, A9 and A10, respectively) through the medial forebrain bundle. Although DA from all three groups acts on the entire dorsal and ventral striatum (Groenewegen et al., 1994), the SNc projections are more closely associated with the dorsal striatum, and the VTA projections are associated with the more ventral, limbic striatum (Fuxe et al., 1985; and Graybiel, 1990). The amygdala is also innervated by all three DA cell groups. The GP is not heavily innervated by DA neurons, so DA has little direct effect on pallidal activity, although it has significant indirect effects. DA terminals and receptors are heavily dispersed throughout the CP and NAcc, and through selective receptors and synapse localization, DA can effect most neurotransmitters located in these nuclei. Approximately 21% of the total axon terminals in the striatum are dopaminergic (Kötter, 1994), and these terminals innervate the GABA medium spiny neurons at more distal areas of the dendrites, areas where Glu terminals synapse with the GABA neurons. The innervation is symmetric on the striatal output neurons, meaning that only one side of the dendritic shaft is in contact with the DA neurons (Smith and Bolam, 1990). Of the five types of DA receptors, D₁ and D₂ receptors are thought to predominate in the striatum. D₁ DA receptors are found primarily on GABA/SP/DYN neurons of the direct BG pathway and on the intrinsic cholinergic neurons. D₂ DA receptors are located primarily on the GABA neurons containing ENK that project to the LPS and on most of the presynaptic terminals of DA, ACh, and Glu neurons (Di Chiara et al., 1994) as indicated in figure 3 on the following page.

The D₁ receptor is stimulatory, and therefore stimulates GABA release to the SNr and MPS, while the D₂ receptor inhibits the release of GABA to the LPS. This, along with excitatory Glu input, is important in maintaining the direct circuit pathway of the BG which serves to inhibit firing of GABA neurons of the output nuclei, and therefore increases the firing of efferents from the motor thalamus (Graybiel, 1990).




FIGURE 3 - Dopamine (DA) innervation and specific receptor localization within the striatum. Spiny neurons of the direct pathway possess mostly D1 DA receptors, as do the cholinergic interneurons, while spiny neurons of the indirect pathway possess D2 DA receptors. Not pictured is that most DA terminals contain D2 DA autoreceptors and NMDA/AMPA receptors.

4. Acetylcholine

Within the BG, ACh is found in the CP and NAcc where its large aspiny interneurons make up approximately 1-2 percent of the total neuronal population of the entire striatum (Graybiel et al., 1986; and Stoof et al. 1992). Its major intrinsic target is the GABAergic output nuclei (Izzo and Bolam, 1988), and it receives direct input from ascending DA neurons, cortical and thalamic Glu neurons, and intrinsic SP projections (Kubota et al., 1987; Chang, 1988; Lapper and Bolam, 1992; Bolam et al, 1986; and Gerfen, 1991). Opiate peptides are also thought to tonically control ACh activity in the striatum (Sandor et al., 1992), and the intrinsic ACh may control its own release through M1, M2, and M4 muscarinic receptors located on the large aspiny interneurons (Bernard et al., 1992).

ACh, like DA, is both stimulatory and inhibitory toward GABA release from the CP. Both striatopallidal and striatonigral GABAergic neurons express M1 and M4 muscarinic receptors (Bernard et al., 1992), but through muscarinic control of c-fos expression in selective striatal neurons, M1 and M4 receptors are thought to differentially influence the two types of medium-sized spiny GABAergic neurons (Di Chiara et al., 1994). Bernard et al (1993) have shown that the muscarinic receptor agonist oxotremorine preferentially stimulates c-fos expression in ENKergic striatopallidal efferent neurons, presumably through M1 receptor stimulation which stimulates phosphoinositol turnover. They relate this to muscarinic tone in the striatum, meaning that although 60% of the ENK/GABA neurons express both m1 and m4 receptor genes, the other 40% express only the m1 gene. They also showed that most of the atropine (a muscarinic receptor antagonist) stimulated c-fos expression occurred in GABA/SP striatonigral neurons, presumably through blocking M4 inhibitory receptors. Di Chiara et al (1994) therefore propose that M1 receptor activity predominates on ENK neurons while M4 receptors are primarily responsible for the cholinergic activity on the GABA/SP/DYN neurons. Therefore, ACh and DA mediate effects opposite one another to influence the release of GABA from the CP through M1/D₂ receptor activity on GABA/ENK striatopallidal neurons and M4/D₁ receptor activity on GABA/SP/DYN striatonigral neurons.

5. Opiate peptides

The opiate peptides ENK and DYN are separately found co-located with GABA in the medium-size spiny neurons of the striatum. As previously indicated in figure 3 on page 8, the GABA/DYN neurons, also co-located with SP, make up the output neurons of the BG direct pathway sending projections to the SNr and the MPS. The GABA/ENK neurons project to the LPS and initiate the indirect pathway of the BG motor loop (Graybiel, 1990). It is likely that endogenous DYN and ENK release in the striatum arise from the recurrent collaterals extending from the striatal spiny projection neurons. The opiate peptides are thought to also be located in the GP and SNr, but only in the terminals of striatal efferent

fibers (Abou-Khalil et al., 1984). Of the three major classes of opioid receptors, μ , δ and κ , all are found, to various degrees, dispersed throughout all BG nuclei. In the rat, μ -receptors are found heaviest in the amygdala, δ are very densely distributed in the striatum, and the κ -receptors are heaviest in the NAcc and part of the amygdala (Mansour et al., 1995). Having both opiate peptides and receptors located in the BG, indicate that ENK and DYN may function in the routine control of neurotransmission through this mass of subcortical neurons.

Opiate peptides are primarily inhibitory toward neurons on which they act, inhibiting both the neuron firing rate and the amount of transmitter released by the neuron (North, 1986). ENK primarily acts at the μ - and δ - type of opiate receptor, while DYN is thought to be the primary endogenous agonist of the κ -receptor. Opiate receptor agonists inhibit neurotransmitter release from neurons throughout the BG. In the mammalian striatum, exogenously applied opiates inhibit the release of ACh, DA, Glu and GABA through an opiate receptor mediate action (Mulder et al., 1984; Werling et al., 1988; and Jiang and North, 1992). GABA release is also inhibited in the GP by opioids (Dewar et al., 1987; and Maneuf et al., 1994), presumably because opiate receptors are located on the striatopallidal presynaptic GABAergic spiny neurons (Abou-Khalil et al., 1984).

Opiate receptor agonists inhibited the release of $[^3\text{H}]\text{-ACh}$ by 50 to 60% of control from rat striatal tissue through the δ -type receptor (Mulder et al., 1984; and Schoffelmeer et al., 1992, respectively), and the release of endogenous ACh primarily through the μ -type receptor and not the δ -type (Lapchak et al., 1989). It has not been suggested, though, if the opiate receptors are located on either the presynaptic terminals of the aspiny cholinergic interneurons or their cell bodies. Although, in the NAcc, μ - and δ - receptors are presumably located on cholinergic terminals (Heijna et al., 1992). The κ -receptor is thought to be located presynaptically on nigrostriatal DA neurons and exert an inhibitory influence on DA release in the striatum (Werling et al., 1988), but selective κ -receptor agonists have no significant effect on DA release in the GP (Dewar et al., 1987). Heijna et

al (1992) have shown also that the κ -receptor agonist U50488 inhibits [3 H]-DA release from the rat NAcc, whereas μ - and δ -receptor agonist inhibit [14 C]-ACh release but had no effect on DA release.

Both μ - and δ - type of opioid receptors are thought to be located on Glu terminals in the striatum arising from cortical excitatory input (Jiang and North, 1992). μ - and δ -, but not κ -, receptor stimulation inhibits synaptic potentials in the striatum mediated by excitatory amino acids; this is interpreted to mean that the opioids are presynaptically inhibiting Glu release (Jiang and North, 1992). It has also been suggested that subtypes of opiate receptors are differentially expressed on the two types of striatal GABAergic neurons (Noble and Cox, 1995). The D_1 DA receptor is preferentially expressed on the striatonigral/endopeduncular neurons, and the A_{2a} adenosine receptor is found primarily on the striatopallidal neurons; both receptors stimulate adenylyl cyclase activity. Noble and Cox (1995) have shown that in rat striatal tissue, μ - and δ_2 - receptors specifically inhibit cyclase activity stimulated by D_1 DA receptors, and δ_1 - and δ_2 -receptors inhibit cyclase activity stimulated by A_{2a} adenosine receptors. This has allowed for the proposed opioid receptor localization on the striatal medium spiny neurons as depicted in Figure 4. μ - and δ_2 -receptors are thought to be located with D_1 DA receptors on striatonigral/endopeduncular neurons, while the δ_1 - and δ_2 -subtypes are co-expressed on striatopallidal neurons.

6. Serotonin

Serotonin innervates the BG through ascending serotonergic projections arising from the raphe nuclei. The dorsal ascending pathway, originating from the nucleus raphe dorsalis, projects mainly to the CP with collaterals leading to the NAcc and GP. The




FIGURE 4 - Opioid receptor localization on medium-size spiny neurons in the striatum. Adapted from Noble and Cox, 1995.

medial ascending pathway, also from the nucleus raphe dorsalis, terminates mainly in the SN, but also sends collaterals to the striatum. The ventral ascending serotonergic pathway arises from the mesencephalic raphe nuclei and projects to the VTA and the medial forebrain bundle (MFB). From the MFB, 5-HT reaches the amygdaloid nuclear complex through the stria terminalis (Steinbusch, 1984).

5-HT mediates both stimulatory and inhibitory actions in the CNS through a broad range of receptor subtypes termed 5-HT₁ (further subtyped B-D) through 5-HT₄ (Julius, 1991). In the striatum, 5-HT inhibits ACh release presumably through 5-HT₂ presynaptic receptors located on cholinergic terminals and cell bodies (Palacios and Dietl, 1988; and Waeber and Palacios, 1994), and GABA release through 5-HT_{1B} receptors located on striatonigral cell bodies (Palacios and Dietl, 1988) and through synaptic contact with the dendritic spines (Soghomoniarn et al., 1989). Direct activity of 5-HT on DA neurons in the striatum is controversial. Ennis et al (1981) state that 5-HT inhibitory receptors are located on presynaptic terminals of DA neurons in the striatum, while others, using lesion studies, show evidence that 5-HT binding sites are not associated with dopaminergic cell bodies, dendrites, or terminals in the striatum (Palacios and Dietl, 1988). 5-HT is also thought to synapse with cholinergic terminals in the ventral pallidum. Immunohistochemical studies indicate that ascending serotonergic neurons innervating the SN primarily terminate in the pars reticulata region (Lovoie and Parent, 1990), and lesion studies indicate that 5-HT synapses with the striatonigral terminals in the SNr which express 5-HT_{1B} receptors (Palacios and Dietl, 1988).

7. Substance P

Substance P is found in medium-size spiny neurons of the striatum (Gerfen, 1992), presumably co-located with GABA and DYN. In the dorsal BG, SP is thought to act specifically on striatal cholinergic interneurons through the SP stimulatory receptor, neurokinin-1 (NK-1) (Gerfen, 1991). Although, immunoreactivity is expressed throughout the striatum, SN, and GP (Haber and Nauta, 1983; and Gerfen, 1991), SP

binding studies have shown dense receptor binding in the striatum and no binding in the SN and only sparse binding in the endopeduncular nucleus, the medial segment of the GP (Danks et al., 1986). This is unusual since these latter two structures are heavily innervated with SP from the striatonigral/endopeduncular projection neurons. *In situ* hybridization histochemistry has indicated the presence of NK-1 receptor mRNA on large cholinergic neurons in the striatum, however no receptor mRNA is thought to exist on the medium-size spiny neurons in the striatum nor on any neurons in the SN (Gerfen, 1992). SP released from recurrent collaterals of the striatonigral/endopeduncular neurons stimulates ACh release by activating NK-1 receptors located on the large aspiny cholinergic interneurons (Gerfen, 1992). In the ventral striatum, lesion studies have indicated that the NAcc sends SP immunoreactive fibers to the ventral pallidum (Haber and Nauta, 1983) that make synaptic contact on numerous cholinergic neurons (Bolam et al., 1986).

Although SP was shown to specifically interact with cholinergic neurons in the striatum and ventral pallidum (Danks et al., 1986; Gerfen, 1991; and Arenas et al., 1991), it has also been shown to stimulate [³H]-DA release from the cat caudate nucleus and met-ENK from rat striatal tissue slices (Baruch et al., 1988; and Del Río et al., 1983, respectively). Release of [³H]-DA from the caudate was mediated by applying SP directly to the pars compacta of the SN, which is contradictory to Gerfen's (1992) interpretation that nigral neurons do not express SP receptors. However, Baruch et al (1988) suggest that SP-stimulated release of [³H]-DA from the cat caudate nucleus is an indirect effect mediated by a "nigro-thalamo-cortico-striatal loop." Del Rio et al (1983) also suggest that SP innervation of met-ENK containing neurons might be indirect through "an interposed cell"; indeed, because NK-1 receptors are not found on striatal spiny neurons (which contain ENK). SP may be stimulating ACh release which in turn stimulates ENK release by activating M1 muscarinic receptors preferentially located on GABA/ENK neurons in the striatum.

C. Metabolic relationship of glutamate and GABA in the CNS

Glu and GABA are closely related neurotransmitters despite their opposing roles in the CNS. As shown in figure 5, Glu and GABA are very similar in structure and have a close metabolic relationship: Glu is the only immediate precursor of GABA, and GABA is one of many metabolic products of Glu metabolism. Both amino acids are

metabolized to various products used in carbohydrate metabolism, and this recycling of metabolites makes it difficult to study Glu and GABA turnover. Glu is metabolized directly from glutamine by glutaminase and from α -ketoglutarate by ornithine aminotransferase. It is also derived from aspartate and α -ketoglutarate through amino-transformation by aspartate transferase, however, which if any of these means of Glu synthesis predominates in glutamatergic neurons has not been fully established. The enzyme responsible for GABA's synthesis, glutamic acid decarboxylase (GAD), is unique in that it serves solely to convert Glu to GABA in GABAergic neurons. This enzyme requires the coenzyme pyridoxal phosphate, and its activity is regulated by both Glu and adenosine analogs (ATP). High levels of Glu and ATP reduce GABA synthesis by preventing proper GAD-coenzyme association (Cooper et al., 1991). GABA transaminase (GABA-T), the enzyme which initiates the primary pathway of GABA metabolism (Lippert et al., 1977), also requires pyridoxal phosphate and is more widely distributed in the body than GAD.

Inhibition of GABA metabolism by inhibiting GABA-T activity has been extensively studied in *in vitro* release experiments as well as clinically as an anticonvulsant. Enzyme




FIGURE 5 - Metabolic relationship of Glutamate and GABA. Abbreviations: GAD, Glutamic acid decarboxylase; PP, pyridoxyl phosphate; GABA-T, GABA transaminase; GDH, glutamate dehydrogenase; OAT, ornithine aminotransferase.

inhibitors such as hydrazides, amino-oxyacidic acid (AOAA), gabaculine, γ -acetylenic GABA, and γ -vinyl GABA (vigabatrin) effectively block GABA-T, but they also show varying degrees of blocking GABA uptake, GABA receptor binding, and GABA synthesis through inhibition of GAD activity (Loscher, 1980). Gabaculine and AOAA, for instance, are the most potent inhibitors of GABA-T, but gabaculine is also a potent inhibitor of uptake, and AOAA shows equipotency at inhibiting GAD activity (Loscher, 1980). Vigabatrin, thought to be one of the most selective inhibitors of GABA metabolism, was found to increase extracellular GABA concentrations in rats primarily through blockade of GABA uptake and not through inhibition of metabolism (Jolkonen et al., 1992). While preventing GABA metabolism will theoretically increase extracellular GABA, blocking Glu metabolism may ultimately decrease GABA content through either direct enzyme inhibition of GAD or through inhibition of GAD-pyridoxal phosphate formation by excess Glu.

D. Pharmacological significance of the glutamatergic and GABAergic synapse in the striatum

GABA activity is thought to be regulated at the synaptic level by both a presynaptic GABA_B receptor and a reuptake transporter. The GABA_B receptor was first discovered in 1981 by Hill and Bowery (1981) to be a novel bicuculline-insensitive GABA binding site that specifically binds baclofen. It was pharmacologically distinguished from the classical GABA_A receptor, but evidence that it acted as an autoreceptor in the CNS was described later when Anderson and Mitchell (1985) showed that baclofen selectively inhibited [³H]-GABA release from the rat median eminence. Through the autoreceptor, baclofen the classical GABA_B receptor agonist, is thought to inhibit GABA release in many brain areas, but in a frequency-dependent manner. Generally, under high stimulated GABA release baclofen has little inhibitory effect, but at basal and low stimulus levels of either 0.5 Hz or 15 mM potassium, baclofen inhibits endogenous GABA release from rat striatum and cortical slices by as much as 60-70 percent (Waldmeier et al., 1988; and Waldmeier and

Baumann, 1990). The extent to which autoreceptors regulate GABA activity within the striatum has not been firmly established, probably because GABA is released from several sites including recurrent collaterals, dendritic spines and interneurons, and it is not known which population of neurons contains GABA_B receptors. For instance, autoreceptor regulation of GABA release is thought to be only on a subpopulation of GABA neurons in the striatum and not on the terminals of recurrent collaterals (Seabrook et al., 1991), because the cell bodies of these neurons, as well as the nigral projection neurons, do not appear to possess functional GABA_B receptors (Waldmeier et al., 1989).

Synaptic GABA uptake is thought to be an important recognition site involved in terminating GABA transmission (Schousboe et al., 1979), and specific uptake transporter inhibitors have been studied as a means of increasing synaptic GABA in *in vitro* and *in vivo* experiments and as potential anticonvulsants. Nipecotic acid and its derivatives are among the most potent inhibitors of GABA transport (Schousboe et al., 1979), but specificity lacks because most derivatives are unable to distinguish the neuronal transporter from the glial transporter (Schousboe et al., 1979; and Larsson et al., 1988), and nipecotic acid may possess substrate affinity for the transporter and displace GABA from intraneuronal stores (Johnston et al., 1976; and Waldmeier et al., 1992). SK&F 89976, a diphenyl-3-butenyl derivative of nipecotic acid, is more potent than nipecotic acid and does not possess transporter substrate activity (Waldmeier et al., 1992). It shows no activity on GABA receptors or GABA metabolism, and its lipophilic moiety allows it to readily cross the blood brain barrier. However, like nipecotic acid, SK&F 89976 blocks both neuronal and glial GABA uptake (Yunger et al., 1984).

Glutamatergic transmission is controlled at its synapse by a high affinity transporter which terminates Glu transmission by transporting Glu from the synapse into either the presynaptic terminal or into glial cells which surround the terminal (Robinson et al., 1991). Various analogs of Glu and kainic acid are known to inhibit Glu transport with varying degrees of potency and selectivity. Threo-3-hydroxyaspartate (THA) is among the most

potent of uptake blockers (Johnston et al., 1979) but possesses significant activity on NMDA receptors (Olferman et al., 1988). Dihydrokainic acid, whose effects were recently studied on *in vivo* Glu release (Fallgren and Paulsen, 1996), is primarily devoid of Glu receptor activity, but is a much weaker blocker of Glu reuptake (Johnston, et al., 1979). L-4-*trans*-pyrrolidine-2,4-dicarboxylic acid (L-*trans*-2,4-PDC) is the most recently discovered selective inhibitor of Glu uptake. It competitively inhibits Glu uptake with a K_i of 4.6 μ M and is considered one of the most potent and preferred inhibitors of the Glu synaptic transporter (Bridges et al., 1991, Kanai et al., 1994). Waldmeier et al (1993) have shown the effects of L-*trans*-2,4-PDC on Glu release from rat cortex tissue. They show that potassium stimulated release of Glu from synaptosomes is decreased significantly by 10 to 300 μ M L-*trans*-2,4-PDC, while basal release is increased 3 to 4 fold under similar concentrations of L-*trans*-2,4-PDC. They, as well as others (Kanai et al., 1994), believe that L-*trans*-2,4-PDC can serve as a substrate for the transporter and displace Glu from its terminal storage sites.

Autoreceptor regulation of Glu release is of some controversy probably because Glu, being an excitatory amino acid (EAA), is historically not known to act on an inhibitory receptor. Pharmacological studies indicate that NMDA receptors are on Glu terminals and mediate an apparent "positive feedback" effect (Errington et al., 1987; and Young and Bradford, 1991), although binding studies in lesioned animals suggests that no presynaptic receptor is present (Greenamyre and Young, 1989). Recent studies (Chittajallu et al., 1996) propose that kainate receptors (non-AMPA) are located presynaptically on Glu terminals of the rat hippocampus and mediate an inhibitory role on Glu release, while earlier reports (Butcher et al., 1987) suggested that kainic acid mediates an *in vivo* release of Glu from the rat striatum, independent of Ca^{2+} .

E. Stimulators of neurotransmitter release

Depolarizing stimuli such as elevated levels of potassium, excitatory amino acid receptor agonists and 4-aminopyridine stimulate release of neurotransmitters from interneuronal stores presumably by inducing an influx of calcium into to the neuron through voltage-sensitive Ca^{2+} channels. Potassium stimulates release of Glu from rat cortical synaptosomes (Waldmeier et al., 1993), *in vivo* Glu and GABA release from rat hippocampus (Rowley et al., 1995) and GABA release from rat NAcc (Smith and Sharp, 1994b), and this release is mediated by potassium induced changes in the neuronal membrane potential. Elevated extracellular potassium weakens the potassium concentration gradient that normally moves potassium out of the neuron; this causes an unbalanced electrical potassium gradient which accelerates potassium influx into the neuron. If nicotinic-ACh receptors are present on these neurons, it is anticipated that their activation will induce depolarization through an influx of Na^+ ions. Depolarization of the neuron, arising from an intracellular increase in positive charge, opens voltage-sensitive Ca^{2+} channels which enables an influx of Ca^{2+} .

The NMDA and AMPA excitatory amino acid receptors both regulate a channel which is permeable to Na^+ and potassium, but the NMDA receptor channel is also highly permeable to Ca^{2+} and is physiologically blocked by the presence of Mg^{2+} . The Mg^{2+} blockade is voltage dependent which means the blockade can be relieved by a depolarization of the neuron by at least 20 to 30 millivolts. The influx of Ca^{2+} through the NMDA receptor channel may serve directly to mediate Ca^{2+} -dependent neurotransmitter release by exocytosis and/or as a carrier of positive charge into the neuron which depolarizes the neuron and ultimately opens voltage-sensitive Ca^{2+} channels (Kandel and Schwartz, 1991). The most significant aspect of opening the NMDA receptor channel is that it is fairly slow and maintains a long-lasting influx of Ca^{2+} . On the other hand, the AMPA receptor mediates a fast and brief influx of Na^+ which evokes a "transient depolarization" that opens voltage-sensitive Ca^{2+} channels (Kötter, 1994). Ultimately,

both NMDA and AMPA receptor activation lead to an influx of Ca^{2+} which may induce neurotransmitter release from neurons on which the receptors are located.

4-aminopyridine (4-AP) is a blocker of the voltage-dependent potassium channel (Albuquerque et al., 1988) and can evoke transmitter release by blocking the channel and subsequently enhancing inward Ca^{2+} currents (Thesleff, 1980). During a neuron's resting state, potassium channels are normally open and the membrane is hyperpolarized; by blocking these channels, the membrane potential becomes more positive and closer to the threshold for neuron depolarization (Kandel and Schwartz, 1991). 4-AP may therefore not evoke "resting" transmitter release and require a small stimulus for depolarization (Thesleff, 1980), however, this is disputed by Hu and Fredholm (1991) who showed 4-AP induced release of [^3H]-noradrenaline in a concentration-dependent manner from rat hippocampal slices without field stimulation.

F. Specific calcium channels involved in axonal and dendritic neurotransmitter release

Exocytotic release of neurotransmitters is mediated by Ca^{2+} entry into presynaptic nerve terminals through voltage-sensitive Ca^{2+} channels (Kandel, 1991). Central neurons contain several types of Ca^{2+} channels which can be pharmacologically defined by specific channel antagonists, and these antagonists have been used to explore the involvement of various Ca^{2+} channels on transmitter release. Immunohistochemical studies have indicated that L-type Ca^{2+} channels exists specifically on cell bodies and proximal dendrites of central neurons (Westenbroek et al., 1992; and Hell et al., 1993), while N- and P-type channels are located on the soma, axon terminals, and the entire length of the dendrites (Hillman et al., 1991; and Westenbroek et al., 1992). The L-type channel blocker, nifedipine, and the N- and P- type blockers ω -conotoxin GVIA (CnTx GVIA) and ω -agatoxin IVa (AgTx IVa), respectively, have been commonly used in identifying specific Ca^{2+} channels involved in Ca^{2+} -dependent transmitter release.

Previous reports have shown that potassium stimulated release of [³H]-Glu and [³H]-DA from rat striatal synaptosomes (ie. from axon terminals) was partially reduced by the P-type Ca²⁺ channel blocker and not affected by the N-type channel blocker (Turner et al., 1993), while release of [³H]-GABA was only sensitive to N-type Ca²⁺ channel blockade (Lecharny et al., 1995). Discrepancies, however, can exist between results obtained with intact synapses and those using synaptosomal preparations, and preloaded [³H]-transmitter release may differ from release of endogenous transmitters (Herdon et al., 1985; Nicholls and Sihra, 1986; and Burke et al., 1993). Endogenous Glu release from striatal slices was reported to be highly sensitive to AgTx IVa, slightly sensitive to CnTx GVIA, but insensitive to nifedipine (Kimura et al., 1995). Burke et al (1993) reported that Glu release from rat hippocampal slices was primarily dependent on Ca²⁺ entry through the P-type channel and to a lesser extent, the N-type, however both P- and N-type channels were involved in GABA release. Takahashi and Momiyama (1993) have also presented similar evidence with selective Ca²⁺ channel blockers on excitatory postsynaptic currents in rat hippocampus and inhibitory GABAergic currents in rat cerebellar and spinal neurons.

The selective localization of the L-type channel on the soma and dendrites of central neurons may indicate the channel's role in cellular functions such as gene expression and enzyme activity (Hell et al., 1993). The channel is also thought to be important in mediating transmitter release from dendrites (Simmons et al., 1995), and release studies in the presence of nifedipine may be a useful tool in identifying dendritic release processes. Simmons et al (1995) have shown that dendritic DYN release from rat hippocampus was sensitive to both L- and N-type Ca²⁺ channel antagonists, while N-type but not L-type channel antagonists inhibited axonal release. GABA release in the striatum is both axonal and dendritic and is therefore likely to be dependent on Ca²⁺ influx through L-, P- and N-type Ca²⁺ channels.

G. Dopamine and opiate interactions in primary cultures of striatal neurons

Functional experiments such as transmitter release and cyclase assays with primary striatal cultures can be distinctly different from other *in vitro* striatal preparations such as synaptosomes and tissue slices: although primary cultures express an abundance of diverse transmitter receptors, they consist of only inherent striatal neurons (primarily GABAergic) and no efferent neurons such as Glu, DA and serotonin, like seen in other striatal preparations. This distinction can enable more direct effects on striatal neurons to be analyzed, and less influence from simultaneous efferent transmitter activity. Receptor expression in striatal cultures also may vary from expression in adult rat striatum, primarily because of embryonic development of striatal receptors. Pharmacological evidence suggests that both D₁ and D₂ DA receptors are expressed in primary striatal cultures derived from fetal rat (Eriksson et al., 1991; and Hoyt and Reynolds, 1996) and fetal mouse (Chneiweiss et al., 1988; Kowalski and Giraud, 1993; and Maus et al., 1993); μ -opiate receptors, as well, are thought to be expressed in primary fetal striatal cultures (McDowell and Kitchen, 1987; Chneiweiss et al., 1988; and Eriksson et al., 1991). Opiate receptor binding studies in rat brain have shown that ontogenesis of δ -opiate receptors was not detected before postnatal day 10 (McDowell and Kitchen, 1986 and 1987), and δ -type receptors appear later than the μ -type during ontogeny (McDowell and Kitchen, 1986 and 1987; and Eriksson et al., 1991). This would suggest a lack of δ -type opiate receptors in primary cultures derived from fetal rat brain. However, reports by at least two separate groups showed functional evidence, through adenylyl cyclase assays, that δ -type opiate receptors are located in primary striatal cultures and are most likely coupled to μ -type receptors (Chneiweiss et al., 1988; and Eriksson et al., 1991). Chneiweiss et al (1988) also presented evidence suggesting that these opiate receptors are located on primary striatal cultured neurons possessing D₁ DA receptors (this was previously discussed in the *opiate peptides* section of the *Introduction* as it pertains to the adult rat striatum).

Stimulated release GABA from primary striatal cultures is elicited by elevated potassium, veratridine, and EAA receptor agonists Glu, aspartate, NMDA, AMPA, kainate and quisqualate (Weiss, 1988a,b; Pin et al., 1989; and Pin and Bockaert, 1989). Little evidence exists that shows GABA release is evoked or inhibited by DA or opiate receptor stimulation. Previous reports have shown that both endogenous (Pin and Bockaert, 1987 and 1989) and [³H]-GABA (Weiss, 1988a and 1990) release from primary striatal cultures induced by potassium was Ca²⁺-dependent and release elicited by EAAs was not. Potassium stimulated release was believed to have occurred through exocytosis, and release stimulated by Glu was thought to result from reversal of the synaptic GABA transporter. Transporter reversal was postulated because release stimulated by EAAs was blocked by nipecotic acid, while potassium depolarization still induced GABA release under identical conditions (Pin and Bockaert, 1989). EAA stimulated release of GABA is also thought to involve a depolarization-dependent reversal of the GABA transporter which is highly dependent on Na⁺. An intracellular accumulation of Na⁺, which follows EAA receptor stimulation, rapidly reverses the Na⁺ gradient required of normal GABA uptake; Na⁺ (and Cl⁻) is instead pumped out of the neuron with GABA (Weiss, 1988a; and Pin and Bockaert, 1989).

H. HPLC analysis of amino acids in biological tissue

Various techniques have been explored for the analysis of amino acids in biological tissue (reviewed by Reynolds and Pearson, 1993), and a commonly used method which is relatively simple and convenient, employs the versatility of reverse-phase high performance liquid chromatography (HPLC) coupled with the sensitivity of electrochemical detection. Isocratic separation of reverse-phase HPLC is based on the hydrophobicity of the amino acids; Glu being fairly hydrophilic compared to GABA. Samples injected into the HPLC pass through a reverse phase column made of carbon-chain resin which separates the contents of the samples primarily through hydrophobic interactions between the sample and

the resin. The more hydrophobic the passing compound, the longer it remains on the column and the later it elutes. Other parameters also influence column separation: the concentration of organic modifier in the mobile phase (ie. methanol or acetonitrile) and the mobile phase pH have significant roles on the separation and elution of the amino acids. The larger the concentration of methanol in the mobile phase the quicker amino acids move through the column, while the more acidic the pH, the longer the amino acids remain on the column, and their column elution time is increased. By varying the separation and elution parameters, optimal separation of the amino acids can be obtained.

Electrochemical detection is used to measure the amino acids as they elute off the column. Unlike the catecholamines, Glu and GABA are not electroactive within the parameters for this type of detection, so they must be derivatized prior to analysis. In this study, the amino acids were derivatized with an o-phthalaldehyde-sulphite (OPA-SO₃) substituent on the amino acid primary amine which renders them electroactive through the sulphite ion (Jacobs, 1987). The reaction is depicted below in figure 6. This method, originally described by Jacobs (1987), is a modification of an original amino acid derivatization assay developed for fluorimetric detection (Lindroth and Mopper, 1979) and later for electrochemical detection (Joseph and Davies, 1983). Pearson et al (1991) as well as others have taken Jacobs' methodology and designed specific parameters for measuring Glu and GABA content in postmortem Huntington's disease brain tissue, GABA release from rat NAcc (Smith and Sharp, 1994a,b), and GABA release from rat hippocampus (Rowley et al., 1995). The precise method of amino acid measurement used in my study was based on both Pearson et al and Smith and Sharp publications, but was




FIGURE 6 - Schematic representation of OPA-SO₃ derivatization of glutamate and GABA. Adapted from Jacobs, 1987.

improved to allow better separation and resolution of Glu and GABA (Phillips and Cox, 1997; and discussed later).

I. Basic hypothesis and specific objectives

I have studied Glu and GABA release from *in vitro* preparations of the rat striatum to evaluate characteristic influences involved in the release of the amino acids. Both neuron localization and specific receptor expression suggests that the amino acid release is regulated by DA, ACh and opiate peptides, as well as other transmitters. I propose that the release of Glu and GABA is regulated by autoreceptor activity and presynaptic transporter reuptake, and that this release is under significant regulatory control by local striatal transmitters. DA is likely to exert a facilitory influence on GABA release through D₁ DA receptors, while μ -opiate receptor stimulation is likely to yield an inhibitory influence.

Amino acid release is studied from striatal tissue slices and fetal rat primary striatal cultures with the major difference in the two being only GABA, and not Glu, is released from the cultures. GABA release from the cultures allows a more focused approach to evaluating striatal GABA release, because there is no endogenous release of DA or Glu which may influence the depolarization-evoked release of GABA.

The primary objectives of this project are: (1) develop a HPLC/electrochemical assay with sufficient sensitivity to measure reliably the amounts of endogenous Glu and GABA released from *in vitro* tissue preparations under basal and depolarizing conditions; (2) obtain selective release stimuli of Glu and GABA and determine the origins of the stimulated amino acid release (axonal and/or dendritic) from striatal tissue slices using selective P-, N- and L- type Ca²⁺ channel antagonists; (3) investigate the striatal transmitters which influence Glu and GABA release under depolarizing conditions; and (4) evaluate the autoreceptor regulation of GABA release, as well as DA and μ -opiate receptor influences on GABA release, from fetal rat primary striatal cultures.

METHODS

A. Assay for glutamate and GABA release from rat caudate-putamen tissue slices

A novel microtiter plate release assay was employed to study the release of the amino acids from rat CP tissue slices. Male Sprague Dawley rats (200-300 g) were euthanatized by decapitation, and the CP immediately dissected from the brain and chopped into 225- μ m slices; the chopped tissue was rotated through 90 degrees and chopped again. (Slices chopped in two dimensions may be referred to as tissue "prisms"; however, for consistency with other literature reports I will refer to the assayed tissue preparation as slices.) The tissue slices were rinsed three times in oxygenated modified Krebs-HEPES buffer (MKB, in mM: 127 NaCl, 5 KCl, 1.3 NaH₂PO₄, 1.2 MgSO₄, 2.5 CaCl₂, 10 glucose, 15 HEPES, adjusted to pH 7.4), then placed in a final suspension of MKB to yield approximately 7.5-10 mg tissue/ml MKB. 200 μ l aliquots of the tissue suspension (1.5 to 2 mg of tissue) were placed into individual wells of a modified 96-well microtiter plate (Millipore Multiscreen, Millipore Corp., Bedford, MA). The plate contains a 0.65- μ m hydrophilic PVDF membrane on the bottom of each well. Under aspiration, buffer passes through the membrane and tissue is retained in the well. The microtiter plate with tissue underwent three separate 5 minute incubations at 37° Celsius in 250 μ l of oxygenated incubation media per well. First incubations contained MKB and receptor antagonists. Second incubations were in MKB and drug contents identical to the first incubation plus receptor agonists where appropriate. The third and final incubations contained contents identical to the previous two incubations plus the releasing stimulus: as discussed later, elevated KCl (20 to 100 mM) with NaCl reduced proportionally to maintain constant ionic strength, 4-AP and NMDA. In other wells, MKB was used in the final incubation to assay basal release. In general, agonists were added to the second and third incubations and antagonist were added to all three incubations when receptor-specific agonist-induced activity was assayed. At the end of each 5 minute incubation period, the microtiter plate

was removed from the incubator and the releasate from the individual wells, about 250 μ l, was filtered under mild vacuum into corresponding wells of a second 96-well plate (a normal 96-well plate without membrane filters). Releasate from each of the three incubations was collected into separate plates; 100 μ l of each releasate sample from the final incubation were used for HPLC analysis of Glu and GABA as described later. Tissue in each well was analyzed for total protein content using a simplified method described by Peterson (1977). All chemicals were from Sigma Chemical Company (St. Louis, MO), and drug receptor ligands were purchased from Research Biochemicals International (Natick, MA), unless otherwise noted. ω -Agatoxin IVa, the P-type Ca^{2+} channel blocker, was a gift from Pfizer Inc. (Groton, CT).

B. Fetal rat primary striatal cultures

The following two media were used in culturing the striatal neurons:

<u>NuSerum containing media (NS-media)</u>	<u>B-27 containing media (B27-media)</u>
Neurobasal medium +	Neurobasal medium +
20 μ M glutamate	20 μ M glutamate
500 μ M glutamine	500 μ M glutamine
10% NuSerum IV *	2% B-27 supplement ++
1% penicillin-streptomycin	1% penicillin-streptomycin
16.6 mM glucose	16.6 mM glucose

Media were filtered through a 0.2 μ m filter into a sterile container. All above products were purchased from Gibco BRL (Gaithersburg, MD) except * purchased from Collaborative Biomedical Products (Bedford, MA). +, Neurobasal medium contains inorganic salts, amino acids and vitamins. ++, B-27 supplement primarily contains steroids, antioxidants and proteins. See Brewer et al (1993) for detailed composition.

1. Plate preparation

Sterile six-well plates were pretreated with 2 ml per well of 1:500 polyethylenimine (PEI) in 50 mM sodium borate pH 7.4 overnight, then washed with PBS pH 7.4 twice before 2 ml of NS-media were added to each well. The plate pretreated with media was allowed to incubate as before for 4 to 24 hours prior to initiation of the culture; incubations occurred at 37° Celsius in 95% oxygen and 5% CO_2 .

2. Fetal striatum dissection and neuron culture preparation

Female Sprague-Dawley rats, 18-day pregnant, under 2.5% halothane anesthesia, were euthanatized by decapitation. The fetuses were removed from the mother and placed into sterile 0.9% saline. Heads were removed from the fetuses and soaked in sterile 70% EtOH for approximately 30 seconds before being washed twice with saline. Heads remained on ice in a petri dish of saline prior to dissection. The striata were dissected out in a petri dish, bathed in Hanks' balanced salt solution with 20 mM HEPES, pH 7.4 (1xHBSS from 10xHBSS in g/L: 1.4 CaCl₂, 4.0 KCl, 0.6 KH₂PO₄, 1.0 MgCl₂, 1.0 MgSO₄, 80 NaCl, 0.9 Na₂HPO₄, 10 glucose; Gibco BRL, Gaithersburg, MD) and stored on ice in 1xHBSS. When dissection was completed, 1xHBSS was removed by aspiration and the tissue was suspended in 2 ml of NS-media; this and the following procedures were conducted under a tissue culture hood. The tissue was triturated into suspension with a fire-narrowed Pasteur pipette and resuspended in 10 ml of NS-media. Cells were counted from an aliquot of the 10 ml suspension using a Coulter Counter ZM (Coulter Electronics, Inc., Hialeah, FL). The tissue suspension was diluted with fresh NS-media at 37° Celsius to yield approximately 1x10⁶ cells/ml. After the NS-Media was removed from the pretreated plates, 2 mls of the final tissue suspension were plated into each well to yield 2x10⁶ cells per well.

After one day of incubation in 95% oxygen and 5% CO₂, NS-media was removed from the plates, and 2 ml of B27-media were added to each well. Serum-free B-27 supplement (with reductions in glutamine concentrations) were important in reducing glial growth in the cultures (Brewer et al., 1993). The primary striatal cultures (PSC) were grown for 7 days at 37° Celsius in 95% oxygen and 5% CO₂.

C. Assay for GABA release from fetal rat primary striatal cultures

GABA release experiments were conducted in the six-well culture dishes using incubation steps similar to the tissue slice release assay described previously. Following the seventh day of incubation, the plates were removed from the incubator and the release assay was conducted on the bench. B27-media contained in each well was removed by aspiration and each well was washed twice with one ml of MKB. The cultured neurons underwent three separate 5 minute incubations at 37° Celsius in 0.75 ml of oxygenated incubation media per well. An "acid wash" of the PSC was conducted in a fourth and final incubation at 37° Celsius for 5 minutes using 0.75 ml of 0.2 N HCl per well. This released a "total amount" of GABA present in each well and allowed for release to be expressed as percent fractional release. GABA content from the second, third and fourth incubations was assayed by HPLC and electrochemical detection; prior to analysis of acid wash samples, 31.5 μ l of 5 N NaOH were added to each of the 0.75 ml of acid wash samples to enable a more optimal sample pH for the derivatization process as described below.

D. Measurement of glutamate and GABA through HPLC analysis

Samples (standards or releasate, but not PSC acid wash samples) containing Glu and/or GABA were derivatized by combining 100 μ l of sample with 20 μ l of internal standard (3.3 μ M homoglutamine) and 12 μ l of OPA-SO₃ solution (22 mg OPA, 0.5 ml 0.0313 M Na₂SO₃, 0.5 ml EtOH, and 9 ml 0.1 M Borax). Because acid wash from PSC release experiments yielded large amounts of GABA, these samples were first diluted 1:7 with H₂O (12.5 μ l of acid wash sample plus 87.5 μ l of H₂O for a 100 μ l sample). Samples, internal standard and OPA-SO₃ reagent were individually filtered through a 0.22- μ m syringe filter prior to mixing. The mixture was allowed to react for 15 minutes at 37° Celsius before 20 μ l of the reaction mixture was injected onto the column. An ESA model 580 solvent delivery module (ESA, Inc., Chelmsford, MA) pumped the mobile phase (0.1 M Na₂HPO₄, 25 μ M EDTA, 5% MeOH, adjusted to pH 5.18 with NaOH) at a consistent

flow rate of 1.2 ml/minute. During method development the mobile phase pH ranged from 5.18 to 5.60. Samples were injected into a 20 μ l injection loop (model 7125, Rheodyne, Inc., Cotati, CA) which preceded the guard column (5 μ m-C18 Microsorb, Rainin Instrument Co., Inc., Emeryville, CA) and reverse phase analytical column (3 μ m-C18, 4.6 x 80 mm HR-80, ESA Inc.). An ESA model 5100A Coulochem detector with guard cell and 5011 dual analytical cell were used for the electrochemical detection. In preliminary experiments it was determined that optimal detector potentials were 650 mV for the guard cell and 350 mV and 600 mV for the D1 and D2 electrodes of the dual analytical cell, respectively. The derivatized amino acids were not affected by the screening 350 mV potential but responded to the second potential of 600 mV by a shift in electrons of the sulphite substituent. This induced a voltage response recorded in microvolts per second which is reported as Area Under the Curve (AUC) for the peak.

After preliminary studies with internal standards used in previously published work, a novel internal standard, homoglutamine (HGLN), was used routinely in quantifying the amounts of amino acids in the tissue releasate (see Results). Standard curves were first established for LCED determination of derivatized Glu and GABA by injecting standards of Glu and GABA in increasing amounts with a consistent amount (10 pmol) of derivatized HGLN. Each injection generated a ratio of AUC of the Glu and GABA peak to the AUC of the 10 pmol HGLN peak. The ratio increased as the amounts of Glu and GABA increased. Glu and GABA standards were diluted to appropriate concentrations from 10 mM stock solutions to yield 1 to 50 pmol amounts in the injected samples. HGLN was also made from a 10 mM stock solution to yield a final amount of 10 pmol in the injected sample. Glu stocks were made in 25% methanol and GABA and HGLN stocks were made in 50% methanol and remained stable for 2 months when stored at 4° Celsius. To determine the amounts of Glu and GABA in the tissue releasates, a ratio of the AUC for the sample peaks of Glu and GABA to the AUC of 10 pmol HGLN in each sample injection

was calculated. This ratio was compared to the AUC ratios of the standard curves, and Glu and GABA content was determined.

LCED analysis of amino acid standards that were not derivatized (contained no OPA-SO₃ reagent) yielded chromatograms with no discernible peaks. Blank samples containing OPA-SO₃ reagent with MKB and no amino acid standards also yielded chromatograms with no discernible peaks which would interfere with the amino acid analysis; only a characteristic solvent front was evident.

E. Statistical analysis

Analysis was conducted on experiments performed in triplicate (or greater) for agonist- and antagonist- induced effects. Analysis of variance (ANOVA) with Scheffe post test was used for analysis of tissue slice release data. *P* values were computed from raw data which were expressed in [pmol amino acid release per mg protein]. Release of GABA from primary striatal cultures was analyzed by paired *t*-test. The total amount of GABA and the amount of GABA released per tissue culture well varied significantly between experiments (ie. different neural preparations) but were relatively consistent within each preparation. Treatments were compared within each culture by paired *t*-test using estimates of fractional release (amount released as percent of total GABA present in the well). Treatments were considered to yield significant effects when *P*<0.05.

RESULTS

A. Development of a sensitive HPLC assay to reliably measure glutamate and GABA release

As discussed earlier, reverse phase HPLC with electrochemical detection of pre-column OPA-SO₃ amino acid derivatives has recently been utilized to measure *in vitro* levels of Glu and GABA (Pearson et al., 1991) and *in vivo* levels of GABA (Smith and Sharp, 1994a,b) in brain tissue. The method I used to assay Glu and GABA release was derived from the above protocols and was discussed in detail in the *Methods* section. However to achieve greater reliability and chromatogram resolution, several steps were undertaken to improve the published methods.

1. Internal standard selection

Amino acids homoserine (HSER), β -aminobutyric acid (BABA) and homoglutamine (HGLN) were used as potential internal standards. HSER is an endogenous amino acid intermediate used by Donzanti and Yamamoto (1988) as an internal standard in an OPA- β -mercaptoethanol method of derivatizing amino acids for HPLC analysis. BABA, an amino acid similar to GABA, was used by Pearson et al (1991) as an internal standard used in the LCED analysis of the OPA-SO₃ derivatized amino acids from brain tissue homogenates. Each internal standard (20 μ l) was derivatized separately with 50 μ l of Glu and 50 μ l of GABA solutions, and 12 μ l of OPA-SO₃ derivatization solution (the stock concentration of Na₂SO₃ was 1.0 M). 20 μ l of the total 132 μ l in the derivatization reaction were injected into the HPLC. The chromatograms in figure 7 show the elution profiles of HSER and BABA (10 pmol) together with Glu and GABA standards (10 pmol each). HSER co-eluted with extraneous peaks under the current chromatographic conditions (figure 7A), and BABA was shown to elute after GABA, as was also shown by Pearson et al (1991), with much less detector response (figure 7B). The elution profile of HGLN, a non-

endogenous amino acid, is shown in figure 8. It yielded a good detector response and eluted between Glu and GABA; it was also free of any apparent co-eluates.




FIGURE 7 - Chromatograms of OPA-SO₃ derivatives of amino acids showing the elution positions of internal standards. Internal standards, HSER and BABA, were derivatized separately with Glu and GABA and 20 μ l (10 pmol each amino acid) were injected into the HPLC as described in the text. In A, homoserine is shown co-eluting with extraneous OPA reagent, and as indicated in B, BABA eluted after GABA and yielded a weak detector response. The eluant pH of both chromatograms was 5.60 and the flow rate was 1.0 ml/minute.

2. Baseline elution of glutamate and GABA

The chromatograms in figure 7 above, as well as in previous reported work by Pearson et al (1991) and Rowley et al (1995) show the derivatized Glu product eluting off of the shoulder of an early eluting front. This large front is most likely a result of excess sodium sulphite in the OPA-SO₃ derivatization solution. The sulphite is the electroactive element of the derivatized amino acids (Jacobs, 1987), and large amounts produce high

current interference which compromise baseline elution of Glu. Figure 8 represents chromatograms of amino acid standards derivatized in an OPA-SO₃ solution containing two different concentrations of sulphite: final concentrations of 50 mM (figure 8A) and 1.56 mM (figure 8B) sodium sulphite. The lower amount of sulphite enabled the derivatized Glu product to elute at the baseline level of the chromatogram without affecting its detector response (compare figures 8A and 8B).




FIGURE 8 - Chromatograms of amino acids derivatized with OPA under different concentrations of sodium sulphite. A: Glu, HGLN and GABA standards were derivatized with OPA solution containing 50 mM sodium sulphite as described in the text and 20 μ l were injected into the HPLC. Excessive amounts of sulphite were injected with the amino acid samples (10 pmol) which caused an initial interference with the baseline elution of Glu. B: Amino acids were derivatized with OPA solution containing 1.56 mM sodium sulphite and a 20 μ l sample was injected into the HPLC. The initial reagent interference is removed by the reduction in sulphite used in the derivatization solution; this allowed the detector response to return to the baseline level prior to the Glu elution. The mobile phase pH used in both chromatographic analyses was 5.41 and the flow rate was 1.0 ml/minute.

The effect of excess sulphite on Glu detection is reflected in the standard curves depicted in figure 9 which were generated from injections of Glu and GABA standards with 10 pmol HGLN internal standard. When derivatized with the larger amount of

Na_2SO_3 in figure 9A, detection of high amounts of Glu was impaired because it eluted on the shoulder of the interfering reaction products. This caused non-linearity in the standard curve for Glu at Glu amounts above 25 pmol. GABA and HGLN responses were not affected. However, with less sulphite used in the derivatization solution, baseline elution of Glu yielded a consistent detector response with a near linear relationship between Glu and the internal standard response up to 50 pmol Glu (figure 9B). Standard curves for the LCED analysis of Glu and GABA were determined in order to quantify unknown amounts of Glu and GABA released from the tissue slice assay.




FIGURE 9 - The influence of the derivatizing sulphite concentration on the linearity of the standard curves of Glu and GABA relative to 10 pmol HGLN internal standard. Glu and GABA (1 to 50 pmol) were derivatized together with 10 pmol HGLN using OPA- SO_3 solutions containing two different concentrations of Na_2SO_3 . A: Standards derivatized with an OPA solution containing 50 mM Na_2SO_3 generated a non-linear curve for Glu at Glu amounts above 25 pmol. B: Standards derivatized with an OPA solution containing 1.56 mM Na_2SO_3 enabled a near linear standard curve for Glu. Curves were assayed in triplicate ($n=3$) and error bars (may not be visible) represent SEM.

3. Effect of mobile phase pH on amino acid separation and elution

LCED analysis of tissue release samples generated many extraneous peaks which interfered especially with Glu separation. Many HPLC parameters contribute to the separation of amino acid derivatives on reverse-phase columns: the length of the column and its particle pore size, the organic modifier in the mobile phase, and the pH of the mobile phase. I found that Glu and GABA were very sensitive to eluant pH changes while early eluting extraneous material which compromised the quantitation of Glu was not. Pearson et al (1991) employed a mobile phase pH of 5.60, however, the Glu reaction product is better separated from interfering peaks at lower pH's. In figure 10 (A and B), chromatograms show samples of Glu and GABA releasate from rat CP tissue slices after stimulation by 50 mM KCl. Samples were derivatized in OPA solution containing 1.56 mM sulphite. Derivatized products in the tissue releasate yielded early eluting peaks in the chromatographic analysis labeled peaks A, B and C. Depending on the eluant pH, Glu could be made to co-elute with any of the peaks. Glu co-eluted with peak B under a mobile phase pH of 5.25 (Figure 10A). Reducing the mobile phase pH to 5.18, resulted in Glu eluting between peaks B and C, and separate from any interfering peaks (figure 10B).

Figure 11 shows the effect of several eluant pH's on the elution times of derivatized Glu, HGLN, GABA and extraneous material in the tissue releasate. Decreasing the pH from 5.54 to 5.18 increased the elution times of both Glu and GABA without greatly altering the elution times of any of the other column eluates. In figure 11A, Glu is shown co-eluting with adjacent peaks A and B at eluant pH's of 5.54 to 5.25, but at pH 5.18 Glu eluted between peaks B and C, separate from any co-eluting electroactive products. Figure 11B shows that the elution time of GABA increased as the mobile phase pH decreased, however the elution of HGLN was not altered. A more acidic mobile phase was not tested since this would further delay the elution of GABA. Because the optimal separation of the Glu reaction product from extraneous tissue constituents was observed at pH 5.18, this eluant pH was used routinely for estimation of Glu in the tissue extracts.






Figure 10. Chromatograms show tissue releasate of rat CP tissue slices under 50 mM KCl stimulation and under basal conditions. The releasate was derivatized for LCED analysis as described in the text. Extraneous material in the releasate sample yielded peaks (labeled A, B and C) on the chromatogram which interfered with the early detection of the derivatized Glu product. A: Under a mobile phase pH of 5.25, Glu co-eluted with peak B. B: The eluent pH was reduced to 5.18, and Glu eluted later, between peaks B and C. GABA elution time was also increased while all other peaks were not greatly affected. C: Typical chromatogram showing basal release of Glu and GABA as described in the text. * The inset shows the basal chromatogram from 12 minutes forward with the display sensitivity increased to better show the GABA peak. The eluent flow rate was 1.2 ml/minute.




FIGURE 11 - The variation of elution times of LCED analyzed Glu and GABA derivatives from tissue releasate under various eluant pH's. A: The elution of derivatized Glu was shown to increase significantly with a consistent reduction in the eluant pH, while surrounding extraneous peaks A, B and C were not affected. This allowed Glu to elute in an ideal position, between peaks B and C. B: The elution time of derivatized GABA increased proportionally to the decrease in the mobile phase pH, while the elution time of the derivatized HGLN was not altered. Curves were assayed in triplicate ($n=3$, except at pH 5.18 $n=5$) and error bars (may not be visible) represent SEM. * Glu co-eluted with the adjacent peak.


B. Characterization of the sources of released glutamate and GABA from rat caudate-putamen tissue slices

Significant levels of Glu and/or GABA were released from the tissue slices by elevated levels of potassium, the potassium channel blocker 4-AP, and the Glu receptor agonist NMDA; exocytotic release was determined by showing that the stimulated release was dependent on the presence of calcium. Specific Glu and GABA reuptake inhibitors were used to evaluate the importance that amino acid reuptake transporters have on the tissue slice release assay design, and Ca^{2+} channels were selectively blocked with specific L-, N- and P-type channel blockers to determine which, if any, type of Ca^{2+} channel is specifically involved in the release of Glu and GABA from the CP tissue slices.

1. Depolarizing stimuli in the release of glutamate and GABA

The effect of increasing potassium concentration on the release of Glu and GABA from CP tissue slices is shown in figure 12A. 1 to 2 mg of tissue were incubated in 250 μl MKB for three separate incubations at 37° Celsius for 5 minutes. The final incubation was in MKB with varying concentrations of KCl from 5 to 100 mM. Release of both amino acids was dependent on the concentration of potassium between 20 and 100 mM. At KCl concentrations above 50 mM, more Glu than GABA was shown to be released, while GABA release increased more gradually from 50 to 100 mM KCl. Figure 12B shows the amounts of amino acids released by potassium as a percentage of maximum release from 100 mM KCl. The EC50 of KCl for the stimulation of Glu release was approximately 55 ± 3 mM KCl, while the EC50 for GABA release was 51 ± 3 mM KCl, based on the linear fits of individual curves. The curves indicate that the stimulated release of both Glu and GABA by 50 mM KCl was fairly equal in sensitivity to potassium depolarization. Experiments conducted over several months showed basal levels of Glu and GABA release to average approximately 325 ± 35 and 144 ± 10 pmol/mg protein, respectively, while potassium stimulated release (50 mM KCl) averaged approximately 4.6 ± 0.2 and 5.5 ± 0.3 nmol/mg protein for Glu and GABA, respectively. Potassium stimulated releasate samples

spiked with Glu and GABA standards gave recoveries of $98 \pm 1\%$ (SEM; n=8) for Glu and $100 \pm 3\%$ (n=8) for GABA.



The calcium-dependency of the release process activated by 50 mM potassium was studied. Tissue washes prior to the release assay were conducted with half the tissue (separated by volume of suspension) in MKB which contained no CaCl_2 and the other half which was in MKB. The control sample incubations were in MKB containing normal amounts of CaCl_2 , and the tested sample incubations were in MKB containing 1 mM

EGTA with CaCl_2 removed. Glu release was reduced to $31 \pm 0.3\%$ of control and GABA release was reduced to $17 \pm 1.2\%$ of control release when calcium was removed from the medium. An influx of calcium into the neuron is believed to be essential for a depolarizing stimulus to elicit transmitter release (Kandel, 1991), and calcium dependency suggests that the majority of the amino acid release was by an exocytotic process.

Several other transmitter releasing mechanisms were evaluated in order to obtain more selective depolarizing agents other than potassium. The potassium channel blocker 4-AP, glutamate receptor agonists NMDA and AMPA, and the nicotinic-acetylcholine receptor agonist, epibatidine, were assayed. Both 4-AP (0.3 and 1.0 mM) and NMDA (10, 25, 50 and 100 μM) stimulated amino acid release from the CP tissue slices; however, AMPA (10, 100 and 500 μM) and epibatidine (5, 50 and 500 nM) failed to yield significant stimulatory effects on the release of Glu or GABA. As indicated below in figure 13A, 4-AP released both amino acids above basal levels in a concentration dependent manner, yet was much more potent and selective at releasing GABA. Basal release of GABA increased nearly five-fold ($488 \pm 51\%$ control release) with 1.0 mM 4-AP, and was considerably higher than Glu release at all concentrations of 4-AP tested. Glu release was increased to $198 \pm 19\%$ control release by the highest amount of 4-AP. NMDA also showed concentration dependent effects on stimulating the amino acid release; however, as shown in figure 13B, efficacy was much greater on Glu release. The maximum stimulatory effect on release was $280 \pm 39\%$ control basal Glu release by 3.0 mM NMDA.

Ca^{2+} dependency studies were conducted on both NMDA and 4-AP stimulated release of Glu and GABA to determine if the release, as seen in figure 13, was occurring through exocytosis and neuron depolarization. The experiments were conducted as described previously; CaCl_2 was removed from the incubation media and 1 mM EGTA was added. Release of GABA by 0.3 and 1.0 mM 4-AP was reduced to $43 \pm 2\%$ and $44 \pm 9\%$ of control stimulated release, respectively (figure 14), indicating that at majority of the release was Ca^{2+} dependent. Selective stimulation of Glu release by NMDA was not dependent on

the presence of Ca^{2+} ; release actually increased 7-fold under 1.0 mM and 5.5-fold with 3.0 mM NMDA when CaCl_2 was removed from the incubation media. NMDA stimulated release of Glu was also not blocked by Mg^{2+} . The lack of both Ca^{2+} dependency and Mg^{2+} sensitivity shows that the release of Glu was most likely not by an exocytotic process, nor mediated through activation of NMDA receptors. Other possible mechanisms of release are considered in the *Discussion* section.




FIGURE 13 - 4-AP and NMDA stimulated release of amino acids from rat CP tissue slices under basal conditions is selective for GABA and Glu release, respectively. A: Basal GABA release was increased to a maximum of nearly 5-fold in a concentration dependent manner by 4-AP, while a much smaller effect was seen on Glu release. B: NMDA stimulated Glu release in a concentration dependent manner without greatly affecting basal release of GABA. A maximum effect was seen at 3 mM NMDA in which Glu release was about 280% of control. Samples of independent experiments were assayed in triplicate and graphs represent data using the following cumulative experiments (n): 4-AP in mM, 0 (13), 0.1 (3), 0.3 (13), 1.0 (12); NMDA in mM, 0 (5), 0.025 (3), 0.1 (3), 1.0 (4), 3.0 (5). ** $P < 0.001$, * $P < 0.01$ (ANOVA, Scheffe post hoc).




Figure 14 - Ca^{2+} -dependency of 4-AP stimulated release of GABA from rat CP tissue slices. Release of GABA by the two highest concentrations of 4-AP tested was reduced by over 50% when CaCl_2 was removed from the incubation media. This suggested that a majority of the release stimulated by potassium channel blockade was through an exocytotic process. Samples were assayed in triplicate, and error bars represent SEM of 3 independent experiments.

2. Effects of specific reuptake inhibitors on glutamate and GABA release

Experiments were conducted to test the effects of specific Glu and GABA reuptake inhibitors on release and to evaluate the importance that the amino acid reuptake transporters have on the release assay design. The GABA transporter blocker nipecotic acid and the Glu transporter blocker L-trans-2,4-PDC, among the most selective and potent reuptake inhibitors commercially available, were used separately in the following tissue slice release experiments. Their activity on both basal and stimulated release were measured using concentrations that are believed not to possess receptor agonist activity. Uptake inhibitors were added to the final two incubations, and release was measured from the final (third) incubation as described in the methods. As depicted in figure 15, nipecotic acid caused over a two-fold increase in the 50 mM KCl stimulated release of GABA and had no effect on the release of Glu, while the Glu reuptake inhibitor increased the stimulated release of Glu by about 50% and only slightly increased stimulated GABA release by $18 \pm 9\%$ with 10 μM L-trans-2,4-PDC (figure 16). Because reuptake inhibitors have a tendency to act as substrates for the transporter and displace the transmitter from internal storage sites, their effects on basal amino acid release was tested, and this is shown in figure 17.




FIGURE 15 - Effect of nipecotic acid on stimulated release (50 mM KCl) of Glu and GABA. GABA release in the presence of nipecotic acid was over 200% of control release at all concentrations tested. Graph represents samples assayed in triplicate in 2 independent experiments with error bars indicating SEM.
* $P<0.05$ (ANOVA, Scheffe post hoc).




FIGURE 16 - Effect of L-trans-2,4-PDC on stimulated release (50 mM KCl) of Glu and GABA. 30 μ M L-trans-2,4-PDC specifically increased the stimulated release of Glu by about 50%. Graph represents samples assayed in triplicate in 2 independent experiments with error bars indicating SEM.
* $P<0.05$ (ANOVA, Scheffe post hoc).




FIGURE 17- Effect of nipecotic acid and L-trans-2,4-PDC on basal release (5 mM KCl) of GABA and Glu. A: Basal release of GABA was increased 4 to over 12-fold by nipecotic acid in a concentration dependent manner. Basal release of Glu was not affected. B: L-trans-2,4-PDC increased basal Glu release to approximately 200% of control, while GABA release was increased slightly. Samples were assayed in triplicate with error bars indicating SEM.

The calcium dependency of nipecotic acid was also assayed to determine if the observed effects were mediated through uptake inhibition or by transmitter displacement. Figure 18, on the following page, shows the effects of nipecotic acid on basal and stimulated release of GABA with CaCl_2 removed from the media and 1 mM EGTA added. The 9-fold increase in basal GABA release by 0.5 mM nipecotic acid was shown not to be dependent on the presence of calcium; basal GABA release elevated by the uptake inhibitor actually increased by a third when calcium was removed (figure 18A). Figure 18B shows that the increase in potassium stimulated release of GABA by nipecotic acid was reduced when CaCl_2 was removed from the media. This apparent reduction in the uptake

inhibitor's effect was most likely a result of the potassium stimulation being dependent on calcium. As previously stated, potassium stimulated release of GABA was normally reduced to 17% of control release in the absence of Ca^{2+} , but in the presence of nipecotic acid release was reduced to only 65% of control.




FIGURE 18 - Effect of nipecotic acid and its calcium dependency on basal and stimulated release of GABA. A: The effect of 0.5 mM nipecotic acid on basal GABA release was shown not to be dependent on the presence of calcium. Nipecotic acid's effect increased by a third when calcium was removed and 1 mM EGTA was added to the media. B: Nipecotic acid increased the potassium (50 mM) stimulated release of GABA to 150% control release, however when calcium was removed, release was reduced to 65% control release. The reduction in nipecotic acid's effect was most likely a result of the potassium stimulation being dependent on calcium and not nipecotic acid's effect being calcium dependent. See text for details. Nipecotic acid had no effect on Glu release in either case. Samples were assayed in triplicate with error bars indicating SEM.

3. Effects of specific Ca^{2+} channel blockers on glutamate and GABA release

Selective Ca^{2+} channels involved in the Ca^{2+} -dependent release of Glu and GABA from the tissue slices by 50 mM KCl and 4-AP were studied using specific Ca^{2+} channel antagonists: the L-, N- and P- type channel blockers nifedipine, CnTx GVIA and AgTx IVa, respectively. Channel blockers were added to the tissue during the second incubation in MKB and the third and final incubation containing the release stimulus. Results are shown in figure 19 and table 1 on the following pages. AgTx IVa yielded the greatest inhibitory effect on potassium stimulated release of both amino acids and GABA release by 4-AP. As shown in figure 19 and indicated in table 1, Glu and GABA release by 50 mM KCl was reduced to $33 \pm 5\%$ and $18 \pm 0\%$ control release, respectively, by 1 μM AgTx IVa. GABA release by both 0.3 and 1.0 mM 4-AP was reduced to $51 \pm 6\%$ and $40 \pm 5\%$, respectively. Effect of AgTx IVa on 4-AP stimulated release of Glu is not shown because of the selectivity of 4-AP on GABA release (see figure 13). Basal release of Glu and GABA was not significantly affected by AgTx IVa. Table 1 shows that neither nifedipine nor CnTx GVIA caused significant inhibitory effects on Glu or GABA release from either stimulus. Values for AgTx IVa, taken from figure 19, are shown in table 1 for comparison purposes and suggests that Ca^{2+} -dependent release of Glu and GABA by potassium stimulation and GABA release by 4-AP stimulation was most likely mediated through P-type Ca^{2+} channels. These inhibitory effects of the P-type channel blocker yielded very similar results as initial Ca^{2+} -dependency studies when CaCl_2 was removed from the media and 1 mM EGTA was added (see figure 14 and its preceding text).




FIGURE 19 - Effect of 1 μ M AgTx IVa on potassium stimulated release of Glu and GABA and 4-AP stimulated release of GABA from rat CP tissue slices. A: Glu and GABA release under 50 mM KCl stimulation was reduced to 33% and 18% control release, respectively ($n=3$). B: GABA release by both 0.3 mM and 1.0 mM 4-AP was reduced to 51% and 40% control release, respectively, by the P-type Ca^{2+} channel blocker ($n=2$). ** $P < 0.005$ (ANOVA, Scheffe post hoc).

Stimulus	50 mM KCl		0.3 mM 4-AP	1.0 mM 4-AP	n
% Cnt Release	Glu	GABA	GABA	GABA	
3 μ M Nifedipine	87 \pm 5	97 \pm 10	79 \pm 16	156 \pm 58	3
10 μ M Nifedipine	72 \pm 13	141 \pm 8	93 \pm 0	97 \pm 16	2
100 μ M Nifedipine	79 \pm 26	97 \pm 18	97 \pm 24	102 \pm 28	2
1 μ M CnTx GVIA	106 \pm 33	101 \pm 19	222 \pm 89	85 \pm 2	2
1 μ M AgTx IVa	33 \pm 5 **	18 \pm 0 **	51 \pm 6 **	40 \pm 5 **	3/2

TABLE 1 - Effects of specific Ca^{2+} channel blockers on potassium- and 4-AP- stimulated release of Glu and GABA from rat CP tissue slices. Both L- and N- type Ca^{2+} channel blockers nifedipine and CnTx GVIA, respectively, caused no significant reduction in the release Glu or GABA. Release in the presence of AgTx IVa was significantly reduced, suggesting that the P-type channel is the primary Ca^{2+} channel responsible for the Ca^{2+} -dependent release of the amino acids. Values are percent control release and represent samples assayed in triplicate in "n" separate experiments with " \pm " indicating SEM.
 ** $P < 0.005$ (ANOVA, Scheffe post hoc).

C. Local transmitter influence on the release of glutamate and GABA from rat caudate-putamen tissue slices

Potassium depolarization of neurons in CP tissue is not a specific stimulus of Glu and GABA release; other transmitters such as ACh and DA are most likely released under elevated potassium. A series of experiments were conducted using selective antagonists of striatal receptors to determine if local transmitters released upon potassium stimulation affected the measured release of Glu and GABA. Antagonists were added to block the receptors of specific striatal transmitters that may have been released along with the detected Glu and GABA, thereby reducing the influence of local transmitters on the release of the amino acids. The experimental design of these ligand studies was discussed in the *Methods* section.

Antagonists selective for Glu, GABA, ACh, DA, and the endogenous opiate receptors were used because these transmitters are known to have significant roles in striatal function, although local regulation of striatal Glu and GABA is not limited to these transmitters. The muscarinic-ACh, GABA and DA receptor antagonists showed significant effects on the release of the amino acids. All caused a decrease in release, but were selective for either Glu or GABA or specific subtypes of receptors. Atropine and saclofen yielded the greatest effects on release and their results are shown in figure 20 on the following page. Atropine, the muscarinic-ACh receptor antagonist, specifically inhibited Glu release in a concentration-dependent manner while not significantly altering GABA release; 10 μ M and 100 μ M atropine reduced the potassium stimulated release of Glu to 72 \pm 7% and 57 \pm 5% control release, respectively. The GABA_B receptor antagonist, saclofen, significantly reduced both Glu and GABA release (figure 20B); the greatest concentration-dependent effects were seen with Glu. Glu release was reduced to 57 \pm 9% and 47 \pm 7% in the presence of 10 μ M and 100 μ M saclofen, respectively. GABA release was reduced to about 78 \pm 5% control release by both concentrations of saclofen.




FIGURE 20 - Effects of atropine and saclofen on potassium-stimulated release of Glu and GABA from rat CP tissue slices. Antagonists were incubated with tissue slices in medium containing 50 mM KCl. A: Atropine, an antagonist at the muscarinic-ACh receptor, specifically reduced the release of Glu by nearly 50% of control without significantly affecting GABA release. B: The GABA_B receptor antagonist, saclofen, caused significant reductions in both Glu and GABA release at concentrations tested. Graphs represent samples assayed in triplicate in 3 independent experiments with error bars indicating SEM.

** $P < 0.005$. * $P < 0.05$
(ANOVA, Scheffé post hoc).

Table 2 on the following page shows results from additional antagonist studies conducted in which results are presented as percent control release. The greatest effects on the amino acid release were seen with atropine and antagonists of both GABA_A and GABA_B receptors, although significance was only found with Glu release with the GABA_A receptor antagonist bicuculline. The D₁ DA receptor antagonist, SCH 23390, reduced Glu release by about 25%, while the D₂ receptor antagonist, eticlopride, did not significantly affect the release of either Glu or GABA in these experiments. CTOP, the μ -opiate receptor antagonist, significantly reduced GABA release, but only at the lower

concentration, negating any concentration-dependent effect. BNTX, a δ_1 -opiate antagonist, and naloxone, the non-selective opiate antagonist were assayed once as a screen for any other opiate mediate activity (data not shown), and they failed to significantly alter the release of Glu or GABA. None of the opiate receptor antagonists tested caused an increase in release, which indicated that no inherent endogenous opiate inhibitory activity influenced the measured release of Glu or GABA.

ANTAGONIST	RECEPTOR	Conc.	Glu	GABA	n
atropine	ACh muscarinic	10 μ M	72 \pm 6 *	112 \pm 9	3
		100 μ M	57 \pm 6 *	87 \pm 10	3
saclofen	GABA _B	10 μ M	57 \pm 6 *	79 \pm 4 *	3
		100 μ M	47 \pm 6 **	77 \pm 5 *	3
bicuculline	GABA _A	10 μ M	60 \pm 6 *	98 \pm 9	2
		100 μ M	58 \pm 3 *	83 \pm 4	2
CPP	NMDA	1 μ M	74 \pm 10	88 \pm 6	3
		10 μ M	91 \pm 9	85 \pm 6	3
CNQX	AMPA	1 μ M	85 \pm 7	107 \pm 6	3
		10 μ M	77 \pm 7	87 \pm 7	3
SCH 23390	D ₁ DA	1 nM	71 \pm 6 *	92 \pm 7	3
		10 nM	74 \pm 8 *	104 \pm 16	3
eticlopride	D ₂ DA	1 nM	69 \pm 10	77 \pm 7	3
		10 nM	71 \pm 10	105 \pm 20	3
CTOP	μ -opiate	100 nM	55 \pm 6	59 \pm 11 *	2
		1 μ M	81 \pm 15	69 \pm 5	2

TABLE 2 - Receptor antagonists of local striatal transmitters: their effects on 50 mM KCl stimulated release of Glu and GABA from rat CP tissue slices. Glu and GABA, measured by HPLC analysis, were released from the tissue by potassium stimulation presumably with other transmitters that were sensitive to potassium-induced depolarization. The effects mediated by antagonists are indicated as percent release of control (50 mM KCl stimulation in the absence of antagonist compared to release in the presence of the antagonist). Results are from samples assayed in triplicate from "n" independent experiments with " \pm " indicating SEM. ** $P < 0.005$ and * $P < 0.05$ (ANOVA, Scheffe post hoc).

Several striatal receptor agonists were assayed for their ability to either inhibit the release of the amino acids from potassium stimulation or stimulate release of the amino acids above basal levels. Selective agonists of the three major classes of opiate receptors were assayed for their ability to inhibit release. The results of these experiments are shown in table 3 below. DAMGO, a μ -selective agonist, DPDPE, a δ_1 -selective agonist, and the κ -selective agonist U69593, were assayed. Of the three agonists assayed, the selective δ -receptor ligand induced a 30-40% reduction of Glu release ($P<0.05$), although GABA release was not affected in a statistically significant manner. The δ_2 -selective agonists, DSLET and deltorphin II, were assayed once (not shown), and they failed to yield any concentration-dependent reduction in Glu or GABA release that would have warranted further experiments. The μ -selective agonist, DAMGO (0.1 and 1 μ M), and the κ -selective agonist U69593 (0.1 and 1 μ M) did not significantly affect potassium stimulated Glu and GABA release.

AGONIST	RECEPTOR	Conc.	Glu	GABA	n
DAMGO	μ -opiate	0.1 μ M	82 \pm 4	121 \pm 13	4
		1 μ M	89 \pm 9	95 \pm 11	4
DPDPE	δ_1 -opiate	0.1 μ M	61 \pm 6 *	98 \pm 11	2
		1 μ M	72 \pm 8 *	114 \pm 12	2
U69593	κ -opiate	0.1 μ M	105 \pm 19	97 \pm 9	3
		1 μ M	86 \pm 12	84 \pm 7	3

TABLE 3 - The effects of selective opiate receptor agonists on 50 mM KCl stimulated release of Glu and GABA from rat CP tissue slices as assayed by HPLC. Only DPDPE selectively reduced Glu release, while GABA release was not significantly altered by any of the agents. Results are from samples assayed in triplicate from "n" independent experiments with " \pm " indicating SEM. * $P<0.05$ (ANOVA, Scheffe post hoc).

The D₁ DA receptor agonist, R(+)-6-bromo-APB HBr (6-Br-APB), was assayed for its potential stimulatory effects on increasing the amino acids release above basal levels and above levels stimulated by elevated potassium. No significant increase in either Glu or

GABA was achieved by the agonist under basal or stimulatory conditions. The results are shown below in table 4.

Release conditions	[6-Br-APB], nM	Glu	GABA	n
5 mM KCl	20	151 ±15	176 ±75	3
	40	134 ±26	123 ±27	3
50 mM KCl	20	83 ±1	79 ±10	2
	40	80 ±5	83 ±5	2

TABLE 4 - Effects of D₁ DA receptor stimulation by 6-Bromo-APB on basal and stimulated release of Glu and GABA from rat CP tissue slices.

Quinelorane, a D₂ DA receptor agonist, was assayed for its potential inhibitory effects on stimulated release of the amino acids. Neither Glu nor GABA release evoked by 50 mM KCl was significantly affected by either 30 or 100 nM quinelorane, and GABA release induced by 0.3 and 1.0 mM 4-AP was also not significantly reduced by the D₂ DA agonist. Because atropine, the muscarinic-ACh receptor antagonist, showed significant inhibitory effects on potassium stimulated release of Glu, it was thought that activation of muscarinic receptors might release Glu above basal levels. Bethanechol, a muscarinic receptor agonist resistant to cholinesterase activity, at 1 mM had no effect on the basal release of either amino acid. The highest concentration tested, 5 mM, stimulated Glu release to 143 ±7% and GABA release to 139 ±14% control release, however this did not reach statistical significance.

D. Endogenous GABA release from fetal rat primary striatal cultures

Striatal neurons were cultured for 7 days prior to the GABA release experiments.

Figure 21, on the following page, shows typical chromatograms of the LCED analysis of the derivatized culture releasate. Unlike releasate from the CP tissue slices in which both Glu and GABA were detected, only GABA was detected in the PSC releasate (figure 21A). Following the culture incubation in stimulus media, a fourth and final incubation was conducted in 0.2 N HCl. This "acid wash" incubation presumably released all contents of the neurons causing large amounts of GABA, as well as Glu, to be extracted into the wash. The large quantities of stored Glu and GABA made it necessary for the acid wash samples to be diluted 8-fold with water for accurate LCED analysis. Figure 21B shows a typical chromatogram of an acid wash sample in which both Glu and GABA were detected. Glu was most likely contained in the GABAergic neurons as a precursor of GABA and not as releasable neurotransmitter, hence its insensitivity to depolarizing stimuli. The measurement of GABA in the acid wash samples was necessary for data to be reported as fractional release. The internal standard HGLN was added to the samples prior to the sample derivatization.

1. Release of GABA by depolarizing stimuli

GABA release from the PSC was stimulated by potassium, 4-AP and Glu. Figure 22 shows typical dose response curves for GABA release by these three transmitter-releasing agents. As described in the methods, the cultured neurons underwent four incubations: the first two were in MKB, the third was in various concentrations of either KCl, 4-AP or Glu, and the fourth was in 0.2 N HCl. Basal release was measured from releasate of the second incubations. GABA release reached a maximum within all the concentration ranges tested for each stimulus. Potassium reached its maximum effect with 80 mM KCl (figure 22A), 4-AP with 0.3 mM (figure 22B) and Glu with 25 μ M (figure 22C). Note that 25 to 100 μ M Glu was as effective as KCl on stimulating GABA release (this was shown in several




FIGURE 21 - Typical chromatograms of LCED analysis of the derivatized culture releasate. Samples were collected, derivatized and injected into the HPLC as described in the text. A: Only GABA, and not Glu, was detected in typical stimulated releasate samples; here, release was induced from 50 mM KCl stimulation. * indicates where a Glu peak would be seen if Glu were released into the sample media. B: Both Glu and GABA were detected in an analysis of a diluted acid wash sample. Dilution of the sample was required because large amounts of the amino acids were released into media following exposure of the PSC to 0.2 N HCl. In both chromatograms the internal standard, HGLN, was added to the samples prior to derivatization.

additional experiments as well). These curves were conducted once each to test for a concentration-dependent trend in the GABA releasing actions of the stimuli. The effects of both KCl (50 mM) and 4-AP were shown to be Ca^{2+} -dependent, however only the lowest concentration of Glu (10 μM) required Ca^{2+} to achieve its effect. Ca^{2+} -dependency was shown by conducting a typical culture release assay except that throughout the experiment CaCl_2 was removed from the MKB and 1 mM EGTA was present. GABA release by 50 mM KCl was reduced to $31 \pm 2\%$ control release; release by 0.3 and 1.0 mM 4-AP was

reduced to $25 \pm 2\%$ and $30 \pm 2\%$ control release, respectively; and release by $10 \mu\text{M}$ Glu was reduced to $11 \pm 0\%$ with CaCl_2 absent from the media.




FIGURE 22 - Release of GABA from PSC by potassium, 4-AP and Glu as a percentage of basal release. A: Release stimulated by potassium was dependent on the concentration of KCl from 20 to 100 mM, and maximum release was achieved with 80 mM KCl. Release by 50 mM KCl was Ca^{2+} -dependent and used throughout further experiments when potassium stimulated release of GABA was assayed. B: 4-AP stimulated release of GABA in concentration ranges from 0.1 to 1.0 mM. The effects of both 0.3 and 1.0 mM 4-AP were Ca^{2+} -dependent. C: Glu was the most effective stimulator of GABA release and reached its maximum effect at 25 μM . However, release by 10 μM Glu, the lowest amount tested, was the only concentration requiring the presence Ca^{2+} . Samples were assayed in duplicate and error bars (may not be visible with 80 mM KCl) represent SEM.

2. Dopamine receptor activity on basal and stimulated release of GABA

The effects of stimulating D₁ and D₂ DA receptors on the release of GABA was studied using DA receptor agonists 6-Br-APB and quinelorane, respectively. 6-Br-APB was assayed for its stimulatory activity on basal release, potassium stimulated release and release stimulated by 4-AP. Figure 23, below, shows the agonist's effect on stimulating GABA release above basal levels. 6-Br-APB, at 3, 30 and 60 nM, was added to individual wells of the cultured neurons in the second incubation from which basal release was assayed. Of the three concentrations tested, the maximum effect was reach with 30 nM 6-Br-APB, and statistical significance was established through separate additional experiments ($P < 0.01$, $n=7$). Percent control basal release was $94 \pm 1\%$ for 3 nM, $175 \pm 18\%$ for 30 nM and $183 \pm 1\%$ for 60 nM 6-Br-APB.




FIGURE 23 - Effect of D₁ DA receptor stimulation on basal release of GABA from fetal rat PSC. 6-Br-APB stimulated the release of GABA above basal levels by increasing release to approximately 180% control release at the two highest concentrations tested. Graph represents samples assayed in duplicate with error bars indicating SEM of duplicates or separate experiments (n): 3 nM (1), 30 nM (7) and 60 nM (1). * $P < 0.01$ (paired t test).

Specific receptor mediated activity was verified by assaying the effects of 6-Br-APB in the presence of a selective D₁ DA receptor antagonist, SCH 23390. Figure 24 on the following page shows that the release of GABA by 30 nM 6-Br-APB was significantly reduced to near control levels in the presence of 30 nM SCH 23390. The agonist

stimulated release to $175 \pm 18\%$ control basal release, but in the presence of the antagonist, release was reduced to $91 \pm 8\%$ control release. SCH 23390, alone, had no effect on the basal release of GABA. This verified that the significant stimulatory effect of basal GABA release by 6-Br-APB was receptor mediated through D₁ DA receptor stimulation.




FIGURE 24 - SCH 23390 blocked the 6-Br-APB stimulation of GABA release from fetal rat PSC. The stimulated release of GABA above basal levels by D₁ DA receptor activation was significantly blocked and reduced to control levels by the D₁ DA receptor antagonist, SCH 23390. This confirmed that the stimulated release of GABA by 6-Br-APB was through D₁ DA receptor activation. Graph represents samples assayed in duplicate from independent experiments with error bars indicating SEM: 30 nM 6-Br-APB (n=7), + 30 nM SCH 23390 (n=2). * $P<0.01$, ** $P<0.005$ (paired t test).

The effect of 30 nM 6-Br-APB on potassium and 4-AP stimulated release of GABA was also assayed. The agonist increased 50 mM KCl stimulated release to $122 \pm 8\%$ control release ($P<0.1$, n=5), but failed to mediate an effect on release stimulated by 0.3 mM 4-AP ($107 \pm 17\%$, n=3). Since no statistical significance of $P<0.05$ was established in either case, agonist effects in the presence of the antagonist were not tested.

The inhibitory effects of D₂ DA receptor stimulation was tested against potassium stimulated release of GABA from the PSC. Quinelorane, at 30 and 100 nM, was incubated with individual wells of cultured neurons in the second and third incubation steps of the release experiment. Elevated potassium (30 and 50 mM KCl) was added to release GABA in the third incubation, and this releasate was assayed for its GABA content. In two separate experiments each, quinelorane did not significantly reduce the potassium stimulated release of GABA.

3. μ -Opiate receptor activity on stimulated release of GABA

The selective μ -opiate receptor agonist, DAMGO, was assayed for its ability to inhibit potassium and 4-AP stimulated release of GABA from the PSC. 1 μ M DAMGO was added to the cultures in the second and third incubations of the release experiment; stimulus was applied to the cultures in the third incubation and its releasate was assayed for GABA content. GABA release induced by either 50 mM KCl or 0.3 mM 4-AP was not affected by μ -opiate receptor stimulation; potassium stimulated release in the presence of DAMGO was $105 \pm 2\%$ control release and release stimulated by 4-AP was $110 \pm 10\%$ control release. The opiate receptor antagonist, naloxone, was used in separate experiments to test for the release of endogenous opiates and their activity on the release of GABA from the cultures. 10 μ M naloxone, present in the second and third incubations, failed to significantly increase 50 mM KCl stimulation of GABA release ($119 \pm 12\%$ control release, n=4) which indicated that under these experimental conditions, endogenous striatal opiates were not affecting GABA release.

GABA released into the culture media may have been acting on striatal GABA autoreceptors and thus reducing the amount of stimulated GABA release detected in the releasate. This reduction in release might have masked any inhibitory effect that μ -opiate receptor stimulation would have on stimulated GABA release. To test this hypothesis, I first examined the autoreceptor regulation of GABA release. GABA_A and GABA_B receptor antagonists were assayed for their effects on potassium stimulated release. An increase in the stimulated release above control levels in the presence of a specific antagonist would indicate that the released GABA is acting on striatal GABA receptors and inhibiting its own stimulated release. In figure 25 on the following page, the effects of selective GABA receptor antagonists on 50 mM KCl stimulation of GABA release are shown. Only the GABA_A receptor antagonist, bicuculline, caused a significant increase in potassium stimulated release of GABA ($143 \pm 18\%$ control release). Release in the presence of the GABA_B receptor antagonists, saclofen and 2-OH saclofen, was $108 \pm 9\%$ and $129 \pm 22\%$

control release, respectively. Bicuculline and 2-OH saclofen together caused potassium stimulated release to increase $57 \pm 26\%$; however, the large variance in these samples prevented the treatment from reaching statistical significance ($P>0.05$).




FIGURE 25 - The effect of GABA receptor antagonism on 50 mM KCl stimulated release of GABA from fetal rat PSC. 100 μ M each of GABA_B receptor antagonists, saclofen (sacl) and 2-OH saclofen (2-OH sacl), and the GABA_A receptor antagonist bicuculline (bicuc) were assayed for their effects on potassium stimulated release of GABA. GABA_B receptor antagonism caused no significant increases in GABA release, while the GABA_A receptor antagonist increased the stimulated release of GABA by nearly 50%. Bicuc and 2-OH sacl together, caused no significant synergistic effect. Results are from independent experiments (n) with error bars indicating SEM: sacl (n=2), 2-OH sacl (n=4), bicuc (n=6), and bicuc/2-OH sacl (n=3).
* $P<0.05$ (paired t test).

Inhibitory effects of μ -opiate receptor activation on the bicuculline increase in potassium stimulated release was tested (figure 26). Although DAMGO (1 μ M) appeared to reduce GABA release in the presence of 100 μ M bicuculline, the reduction was not statistically significant ($P>0.05$). Bicuculline increased the stimulated release to $143 \pm 18\%$ control, and in the presence of DAMGO, bicuculline's effect was $107 \pm 15\%$ control release.




FIGURE 26 - Effect of DAMGO on the bicuculline increase in 50 mM KCl stimulation of GABA release from fetal rat PSC. The GABA_A receptor antagonist, bicuculline (bicuc, 100 μ M), increased potassium stimulated release of GABA to 143% of control release, however in the presence of 1 μ M DAMGO, this effect was reduced to 107%. Statistical significance was not reached for the DAMGO effect, however. Results are from independent experiments (n) with error bars indicating SEM: bicuc (n=6) and bicuc/DAMGO (n=5).
* $P < 0.05$ (paired t test).

DISCUSSION

A. HPLC and electrochemical detection of glutamate and GABA

The initial objective of this project was to obtain a reproducible assay that would allow endogenous Glu and GABA released from striatal tissue to be measured by sensitive and reliable means. Because measuring endogenous Glu and GABA simultaneously from one releasate sample is a fairly new concept and very important for the basis of this project, a majority of the time spent on preliminary experimentation went into the development of the assay parameters. The methods employed by Pearson et al (1991) and Smith and Sharp (1994a,b) were used in establishing the basic method for HPLC and electrochemical detection of amino acids, but the methods required modification to improve the detection reliability. More recent work by Rowley et al (1995) was used to verify these unique improvements for measurement of endogenous Glu and GABA through LCED analysis of their OPA-SO₃ derivatives. The revised method has recently been published (Phillips and Cox, 1997).

Electrochemical analysis of sulphites, originally described by Jacobs (1987), has been used frequently for amino acid detection in brain homogenates (Pearson et al., 1991) and microdialysis preparations (Smith and Sharp, 1994b and Rowley et al., 1995). Several problems with this method of HPLC analysis were apparent: previously used amino acid internal standards compromised the efficiency of the LCED analysis, and amino acids such as Glu that elute early in the chromatogram are susceptible to interference by excess sulphite as well as other reaction products and tissue constituents.

The internal standards, BABA (Pearson et al., 1991) and HSER (Donzanti and Yamamoto, 1988), were first evaluated because of their previous reported use. BABA yielded a weak detector response and increased the chromatographic analysis time, while HSER co-eluted with extraneous material in the standard injections under my HPLC parameters. It should also be noted that HSER is an amino acid intermediate found

endogenously in biochemical reactions (Voet and Voet, 1990); this may compromise its use as an internal standard in the LCED analysis of tissue amino acid levels. An internal standard is an amino acid that is combined with the sample containing Glu and GABA; it undergoes derivatization and is injected into the HPLC with each sample. It serves several important functions: it verifies that the sample separation and detection is running normally, that the derivatization reaction is occurring properly, and it serves to establish a standard curve for quantifying unknown amounts of Glu and GABA released from the tissue. The internal standard used in quantifying Glu and GABA release ideally should be a non-endogenous amino acid that elutes between Glu and GABA. HGLN is not an endogenous amino acid, and its structure indicated to me that its derivatized product would likely elute between Glu and GABA. HGLN was found to elute later than HSER and just after the extraneous column eluant that co-eluted with HSER. Stock solutions of HGLN tested repeatedly showed stable elution times and gave consistent detector responses over many experiments. It was subsequently used in all LCED analyses of Glu and GABA release from the tissue slices and GABA release from the PSC.

The amount of sulphite used in the derivatization media was shown to be critical in the baseline elution of Glu, and hence the standard curve of Glu. Rowley et al (1995) discussed sulphite contamination briefly, and reduced the amount of derivatizing agent only when dialysis samples were derivatized. I found it beneficial to specifically reduce the sulphite much further and maintain a consistent amount used in both the measurement of standards for standard curves and in the sample releasate analysis. The reduction in sulphite concentration did not alter the magnitude of the detector response to derivatized amino acids including Glu, GABA and HGLN. It appears the concentration is still in large excess for the derivatization reaction. I also used a dual analytical cell to apply two positive potentials to the column eluates: an initial low voltage was used to screen out potential interference, while the derivatized amino acids were detected through the second potential which was higher. The first applied potential of 350 mV was helpful in reducing the

detected response of the extraneous peak which eluted just prior to the HGLN peak (data not shown).

Adjustment of the sulphite concentration in the derivatization solution led to significant improvements in the amino acid standard curves, however releasate samples from both *in vitro* and *in vivo* amino acid analysis produced extraneous materials which were detected in each LCED analysis of OPA-SO₃ derivatized amino acids. Most of this material produced peaks seen very early in the chromatogram, around the elution time of the Glu reaction product. This had little bearing on GABA detection but significantly compromised the quantitation of Glu. I showed that Glu and GABA were sensitive to mobile phase pH changes while most other electroactive eluates were not, within the pH range tested. Reduction of the sulphite concentration used in the derivatization and appropriate adjustment of the mobile phase pH gave baseline separation of both Glu and GABA. This ultimately enabled a more accurate measurement of the derivatized Glu product and a more reliable standard curve for Glu.

The *in vitro* multi-well filter-plate release assay was significant in the study of Glu and GABA release primarily because it enabled the analysis of numerous samples from various pharmacological treatments within individual experiments. Other *in vitro* tissue slice release assays were considered. Superfusion, which is commonly used in radiolabeled transmitter release analysis (i.e. Jacocks and Cox, 1992), generates large amounts of separate releasate samples (superfusates), and transmitter release of individual samples (and the pharmacological effect) is studied over a series of superfusates. LCED analysis of endogenous amino acid release through superfusion would require a significant amount of time to analyze the separate superfusates of individual samples. A multi-well plate system for the study of Glu and GABA release from tissue slices was more applicable for this project, making it possible to obtain the required data within a reasonable period of time. Several trial experiments were conducted using an alternative multi-well plate assay. This assay, previously used by Werling et al (1988) to study [³H]-dopamine release from rat

striatum and cortex tissue slices and Kim and Cox (1993) for the study of [³H]-norepinephrine release from rat cortex tissue slices, employs a 24-well plate with a removable basket-insert tray to handle tissue slices. Larger wells are used in this system which require larger amounts of buffer, drug or peptide, and tissue, compared to the 96-well microtiter plate. Considering the size of the rat striatum and the study of endogenous transmitters, it was much more feasible to use the 96-well microtiter plate which has smaller wells for tissue and buffer distribution; this permits the recovery of a more "concentrated" releasate. The most notable disadvantage of studying transmitter release with this type of multi-well assay plate procedure, is that transmitters are released into a "static-well" environment. Thus Glu and GABA are released into the buffer containing the tissue for the duration of the tissue incubation or release period, unlike superfusate which is nearly instantaneously superfused from the tissue, depending on the flow rate of superfusion. A static-well releasate system may permit the released transmitters to augment or reduce their own release through autoreceptor regulation or presynaptic re-accumulation. The disadvantage of this approach is that the observed "release" is a sum of release and reuptake process. The advantage is that this may closely parallel the *in vivo* situation.

B. Release of glutamate and GABA from rat caudate-putamen tissue slices by depolarizing stimuli

Release of Glu and GABA was stimulated by elevated potassium, 4-AP and NMDA. Potassium stimulated release of both amino acids in a concentration dependent manner, while 4-AP selectively released GABA, and NMDA was more efficacious toward Glu release. Release stimulated by 50 mM KCl and 4-AP was Ca²⁺-dependent, however NMDA stimulated release of Glu was not; NMDA evoked release of Glu was also not affected by the presence of Mg²⁺.

The Ca²⁺-dependency of Glu and GABA release suggests that a majority of release was occurring primarily through exocytosis (Kandel, 1991). However, 31% of Glu

release and 17% of GABA release evoked by potassium was not Ca^{2+} -dependent, as was about 44% of GABA release stimulated by 4-AP. The Ca^{2+} -independent release seen with these depolarizing agents may have resulted from a portion of release being dependent on Na^+ . Norris et al (1983), Carvalho et al (1986), Bernath and Zigmond (1990) and others have shown that depolarization evoked transmitter release is blocked by Ca^{2+} channel antagonists even in the absence of external Ca^{2+} . Bernath (1992) interprets this as meaning ionic influxes still occur through Ca^{2+} channels when external Ca^{2+} is absent. He, as well as others, also suggest that transmitter release evoked through depolarization in the absence of Ca^{2+} is solely dependent on the presence of external Na^+ , and that Na^+ is transported through voltage-dependent Ca^{2+} channels during depolarization, particularly when residual Ca^{2+} is bound by chelators such as EGTA (see for review Bernath, 1992). The Na^+ -dependency of release in the absence of Ca^{2+} was not evaluated in my experiments. However, it provides a possible explanation for potassium and 4-AP evoked transmitter release to not be entirely dependent on external Ca^{2+} .

The selectivity of NMDA to specifically evoke Glu release suggests a distinct localization of EAA receptors on Glu neurons or a unique interaction of NMDA with the Glu transporter. The maximum effect of NMDA on Glu release was achieved only at a concentration of 3 mM which may be a significantly higher concentration than that required to normally activate NMDA receptors. NMDA was shown to inhibit [^3H]-Glu binding in rat brain postsynaptic densities with a K_i of 7.2 μM (Fagg and Matus, 1984) and stimulate GABA release and [^3H]-GABA release from striatal cultures with EC50's of 19 μM and 22 μM , respectively (Pin et al., 1988; and Jouanen et al., 1991). At a concentration of 3 mM, NMDA may be activating AMPA receptors or altering the uptake of Glu. However, I was unable to show that AMPA could release Glu or GABA from the tissue slices, and selective Glu receptor antagonism in the presence of NMDA receptor stimulation was not explored; this would have deviated from the central focus of the project.

Much controversy exists as to whether NMDA receptors are expressed presynaptically in the striatum. Greenamyre and Young (1989) use autoradiography and lesion studies to report that the majority of NMDA receptors in the striatum are located postsynaptically, and they provided no support that NMDA receptors are presynaptically located on Glu terminals. However, Ohta et al (1994) showed evidence suggesting that NMDA as well as AMPA receptors exist on monoaminergic terminals throughout the striatum, and Young and Bradford (1991) and Errington et al (1987) produced pharmacological evidence indicating that NMDA receptors are on Glu terminals to mediate an apparent "positive feedback" on Glu release. Two lines of evidence suggest that NMDA stimulation of Glu release was not receptor mediated: I showed NMDA stimulation of Glu release to be Ca^{2+} -independent and insensitive to the presence of Mg^{2+} . This does not necessarily preclude a receptor mediated action of NMDA. However, because NMDA only released Glu and not GABA, it is likely that NMDA was acting on the synaptic Glu transporter and releasing Glu through reversal of the transporter. NMDA receptor stimulation, in the absence of external Ca^{2+} , can evoke depolarization-induced reversal of the presynaptic transporter by increasing the internal Na^+ concentration (Weiss, 1988a; Pin and Bockaert, 1989; Weiss, 1990; and Bernath, 1992). Large amounts of NMDA may stimulate AMPA receptors enough to relieve the Mg^{2+} block on local NMDA receptors, thereby increasing Na^+ influx through the AMPA or NMDA receptor channel. Also, I found that 1 and 3 mM NMDA stimulation of Glu release increased approximately 6-fold in the absence of external Ca^{2+} , and that basal GABA release by these concentrations of NMDA was increased by over 12-fold (data not shown). This may be indicative of Na^+ -dependent, depolarization-induced reversal of presynaptic transporters as discussed above, whereby large amounts of Na^+ entered the neuron through voltage-sensitive Ca^{2+} channels that were unoccupied by external Ca^{2+} (Bernath, 1992).

The insensitivity of GABA release from the slices by NMDA and the selective actions of 4-AP on GABA release requires some explanation. Although GABAergic medium-size

spiny neurons in the striatum are thought to possess NMDA receptors. Di Chiara et al (1994) proposed that NMDA-receptor influence of GABA activity is most likely mediated indirectly through Glu's primary action on NMDA receptors located on cholinergic neurons. GABA is the "fast inhibitory transmitter" in the striatum and receives fast excitatory input from Glu which utilizes AMPA receptors; NMDA receptors mediate a slower response and function in a modulatory role in the striatum, much like DA and ACh do (Di Chiara et al., 1994). It is likely that the tissue slices under my experimental conditions were unable to show "modulatory" activity of NMDA receptor stimulation: incubating the tissue for 5 minutes with such large amounts of NMDA was not optimal conditions for obtaining either NMDA evoked cholinergic activity or release of enough ACh by NMDA to influence GABA release. 4-AP, on the other hand, was a very effective stimulator of GABA release; basal release increased nearly 5-fold with 1.0 mM 4-AP. GABA release, arising from interneurons, recurrent collaterals and dendrites, may have a greater sensitivity to voltage-sensitive potassium channel blockade, while Glu release, which comes entirely from terminals of long efferent neurons, may express less of the 4-AP-sensitive potassium channels.

C. Significance of presynaptic reuptake on potassium-evoked release of glutamate and GABA from rat caudate-putamen tissue slices

Both Glu and GABA are removed from the synaptic extracellular space by specific reuptake transporters that re-accumulate the amino acids back into the presynaptic terminal or into surrounding glia (Schousboe et al., 1979; and Robinson et al., 1991). I studied the effects of specific Glu and GABA reuptake inhibitors on potassium stimulated release of the amino acids to determine if presynaptic reuptake played a significant role in the tissue slice release assay. The stimulated release of both Glu and GABA was shown to increase significantly in the presence of their selective reuptake blockers, and this effect was shown to be fairly selective. Nipecotic acid significantly increased the potassium- (50 mM)

stimulated release of GABA by over 2-fold at all concentrations tested and had little effect on Glu release. A slight, yet statistically significant increase in Glu release was observed at the highest concentration of L-trans-2,4-PDC. This did not necessarily suggest, though, that a *significant* level of released amino acids were being transported into their respective synapse in the absence of the transporters.

Further studies were necessary to determine if nipecotic acid or L-trans-2,4-PDC were mediating their effects through transporter inhibition and not through uptake and transmitter displacement. Both blockers caused an increase in basal release of the amino acids.

Nipecotic acid increased basal GABA release in a concentration-dependent manner to over 12-fold at its highest concentration, and basal Glu release was increased by 2-fold with 30 μ M L-trans-2,4-PDC. The effect of nipecotic acid on both stimulated and basal release of GABA was also shown not to be dependent on Ca^{2+} , indicating that the observed effects were not through depolarization-induced exocytotic release. It is important to note that the stimulatory effects of both uptake inhibitors on basal release was greater than their effects on 50 mM KCl stimulated release. This, again, suggests that their effects on release were not a result of uptake inhibition; it is unlikely that more transmitter was being taken up during basal release than during stimulated release.

Previous reports have shown that nipecotic acid, the prototypic GABA uptake inhibitor, possesses substrate affinity for the transporter and is capable of releasing GABA from neuronal stores (Johnston et al., 1976; and Waldmeier et al., 1992). Nipecotic acid itself is taken up into GABAergic neurons and released by potassium depolarization in a Ca^{2+} -dependent manner (Johnston et al., 1976), suggesting that it incorporates into synaptic vesicles and displaces GABA into the synaptic cytoplasm. L-trans-2,4-PDC, too, despite its high potency and preferential use as a Glu neuronal reuptake inhibitor, has been reported to possess substrate affinity for the Glu transporter and to release neuronal stores of Glu (Waldmeier et al., 1993; and Kanai et al., 1994).

These results, combined with reports discussed above, led me to consider that the significant increases in release of the amino acids observed in the presence of their respective uptake inhibitors was not a result of significant reuptake inhibition, but rather the release-evoking effects of the transporter blockers. These considerations, however, do not rule out the importance of transmitter reuptake *in vivo* or in the experimental design, but blockers with greater specificity were not commercially available, so further studies on uptake inhibition were not explored.

Amino acid neurotransmitter synaptic reuptake transporters are thought to operate less efficiently under elevated potassium depolarization because of significant alterations in the Na^+ concentration gradients and membrane potential and inhibition of Na^+ binding to the transporter (Bernath, 1992). Also, GABA release by the voltage-dependent potassium channel blocker, 4-AP, is accompanied by prolonged depolarization of the neuron (Thesleff, 1980), and this significant alteration in the membrane potential is likely to reduce the Na^+ concentration gradient necessary for GABA transport. Hence, potassium depolarization-evoked release of Glu and GABA, or GABA release evoked by 4-AP is most likely not altered in a significant manner by active presynaptic transporter reuptake.

D. P-type calcium channel involvement in the calcium-dependent release of glutamate and GABA from rat caudate-putamen tissue slices

The specific Ca^{2+} channels involved in the potassium- and 4-AP- evoked Ca^{2+} -dependent release of Glu and GABA from the CP tissue slices were investigated to determine the primary origins of the released amino acids. Three major classes of Ca^{2+} channels in the CNS are the L-, N- and P- types, and as discussed in the *Introduction*, they are thought to be expressed on specific areas of central neurons. Because L-type channels are uniquely located on proximal dendrites and the soma, and not the axon (unlike the N- and P- types which are located on the entire neuron including the axon), I had proposed that proximal dendritic release of GABA could be identified by its sensitivity to nifedipine,

the L-type channel blocker. Glu release, arising only from the axons of efferent neurons, should not be sensitive to nifedipine and only sensitive to either N-type blockade by CnTx GVIA or the P-type blockade of AgTx IVa.

I showed that only AgTx IVa was effective at significantly reducing the Ca^{2+} -dependent release of Glu and GABA by KCl depolarization and GABA release by 4-AP. Contrary to my predictions, nifedipine had no significant inhibitory effects on GABA release and CnTx GVIA failed to alter either amino acid release significantly. AgTx IVa (1 μM) reduced 50 mM KCl stimulated release of Glu and GABA to $33 \pm 5\%$ and $18 \pm 0\%$ control release, respectively; GABA release by 0.3 and 1.0 mM 4-AP was reduced to $51 \pm 6\%$ and $40 \pm 5\%$ control release, respectively. The inhibitory effects of 1 μM AgTx IVa reached statistical significance ($P < 0.005$) in all cases, and when compared to initial Ca^{2+} -dependency studies (CaCl_2 removed from the media and 1 mM EGTA added), all Ca^{2+} -dependent release by potassium depolarization appears to be entirely contingent upon external Ca^{2+} influx through the P-type voltage-sensitive Ca^{2+} channel. For example, I showed that in the absence of external Ca^{2+} with EGTA present, 50 mM KCl stimulated release of Glu and GABA was reduced to $31 \pm 0.3\%$ and $17 \pm 1.2\%$ control release, respectively; this is very comparable to $33 \pm 5\%$ and $18 \pm 0\%$ control release for Glu and GABA, respectively, under 50 mM KCl stimulation with external Ca^{2+} and AgTx IVa present. The Ca^{2+} -dependent release of GABA by 4-AP depolarization also appeared to be entirely dependent on Ca^{2+} influx through the P-type Ca^{2+} channel. GABA release by 0.3 mM and 1.0 mM 4-AP was reduced to $43 \pm 2\%$ and $44 \pm 9\%$ control release, respectively, with external Ca^{2+} removed, compared to $51 \pm 6\%$ and $40 \pm 5\%$ control release, respectively, with external Ca^{2+} and AgTx IVa present.

The insensitivity of Ca^{2+} -dependent GABA release to nifedipine does not necessarily indicate that GABA release under these experimental conditions was not of a dendritic source. It does however show that L-type Ca^{2+} channels were most likely not involved in the Ca^{2+} -dependent release of the amino acids. Simmons et al (1995) showed dendritic

DYN release to be specifically sensitive L- and N- type Ca^{2+} channel blockade, while axonal release was only sensitive to N-type channel blockade. This was performed, however, using electrical stimulation of hippocampal tissue and under various other different experimental conditions. In the CP, dendritic release of GABA may occur and probably does occur *in vivo*, and the L-type Ca^{2+} channel may play a role in Ca^{2+} -dependent transmitter release; but under my experimental conditions, the Ca^{2+} -dependent release of GABA was solely dependent on Ca^{2+} influx through the P-type channel, and the L-type channel, according to Hell et al (1993), may have only performed its role in cellular functions such as gene expression and enzyme activity, not transmitter release. As discussed in the *Introduction*, previous reports showed that in rat striatal synaptosomes only N-type Ca^{2+} channels were involved in Ca^{2+} dependent release of [^3H]-GABA (Lecharny et al., 1995), and the P-type, and not the N-type of Ca^{2+} channel, was involved in Ca^{2+} -dependent release of [^3H]-Glu (Turner et al., 1993). Endogenous Glu release from striatal slices was also shown to be primarily dependent on Ca^{2+} influx through the P-type channel (Kimura et al., 1995).

E. Local transmitter influence on amino acid release from rat caudate-putamen tissue slices through actions of specific receptor ligands

50 mM KCl was shown to be an effective depolarizing stimulus of Glu and GABA release, however, elevated potassium is not a specific release stimulus: other striatal transmitters such as DA, ACh and opiate peptides were also likely released under potassium depolarization of the CP tissue slices. The analysis of these released transmitters was not in the scope of my project; however, I did intend to evaluated their influence on the measured release of Glu and GABA. Antagonists of muscarinic-ACh, DA, opiate peptides as well as Glu and GABA receptors were used to block effects, if any, of striatal transmitters on potassium stimulated release of the amino acids. A striatal transmitter was

thought to affect Glu and/or GABA release if that transmitter's receptor antagonist increased or decreased the measured amount of Glu and GABA in the tissue releasate.

Of the receptor antagonists assayed, atropine, saclofen, bicuculline, and SCH 23390 showed significant effects on release. Atropine specifically reduced Glu release by as much as 50% indicating a possible cholinergic influence on the stimulated release of Glu. The GABA_B receptor antagonist, saclofen blocked release of both amino acids. This antagonist effect indicated, in this release assay, that the released GABA was not acting on GABA_B autoreceptors to inhibit its release presynaptically; if it were, GABA release would have increased in the presence of the antagonist. Glu release was also reduced by bicuculline, the GABA_A receptor antagonist, suggesting that the released GABA may have indirectly affected Glu release through some disinhibitory mechanism. For example, if 5-HT is inhibitory on Glu release in the striatum, and in turn GABA reduces the 5-HT input to the Glu neurons through both types of GABA receptors, then blocking these receptors would have relieved the GABA inhibition of 5-HT and thereby enabled 5-HT to reduce Glu release. A similar situation may be the reason for saclofen reducing GABA release, except that the disinhibition of the input into the GABA neurons is mediated only through the GABA_A receptor. A dopaminergic influence on Glu release within this assay may be indicative of the results with SCH 23390, however the inhibitory effect of the D₁ DA antagonist was not concentration-dependent within the two concentrations tested. DA is most likely released with Glu, GABA and ACh following potassium depolarization, and it may have been acting on Glu neurons through the D₁ DA receptors to augment Glu release. By blocking these receptors, DA influence on Glu release was removed and Glu release decreased.

Because significant effects of the antagonists tested above were inhibitory toward release, it seemed likely that their corresponding receptor agonist would stimulate release. With exception of the GABA receptor antagonists, the direct effects of the antagonists could be interpreted so that bethanechol, a muscarinic-ACh receptor agonist, and 6-Br-

APB, the D₁ DA receptor agonist, would likely stimulate Glu release in the tissue slice assay. Both receptor agonists, however, failed to release Glu or GABA to levels significantly above basal release. Thus, under these experimental conditions, the inhibitory effects of the antagonists do not necessarily suggest that their corresponding receptor agonists elicit the opposite effect (i.e. stimulate Glu release). Of the opiate receptor agonists tested for their inhibitory role on potassium stimulated release, only the δ₁-agonist, DPDPE, yielded statistically significant effects, yet these effects were not concentration-dependent. It was especially surprising that neither μ-opiate receptor or D₁ DA receptor stimulation yielded any significant effects on GABA release, considering the localization of μ-opiate and D₁ DA receptors in the striatum.

F. GABA release from fetal rat primary striatal cultures

In view of the complex regulation of transmitter release in adult CP and the difficulty in observing inhibitory regulation of GABA release, the regulation of GABA release from primary cultures of embryonic rat striatal neurons was explored.

1. Release of GABA by depolarizing stimuli

Significant levels of GABA were released from the PSC by potassium, 4-AP and Glu. Release evoked by 50 mM KCl and 0.3 and 1.0 mM 4-AP was most likely through exocytosis because a majority of the release was Ca²⁺-dependent; release stimulated by Glu, however, appeared less dependent on external Ca²⁺. Release evoked by 10 μM Glu, the smallest concentration tested, was Ca²⁺-dependent and reached a 3-fold increase in basal GABA release, similar to release stimulated by 30 mM KCl. However, release was independent of external Ca²⁺ when stimulated by larger amounts of Glu (25, 50 and 100 μM), and this release was slightly larger than release stimulated by 80 mM KCl, the most effective concentration of KCl for potassium depolarization. Of the three depolarizing agents tested, Glu was the most efficacious stimulus of GABA release, while potassium was clearly the most effective stimulator of Ca²⁺-dependent release under these

experimental conditions. It is not surprising that Glu evoked Ca^{2+} -independent release of GABA from the PSC: in fetal mouse cultures, EAAs were shown to evoke Ca^{2+} -independent release of both [3H]-GABA (Weiss, 1988a) and endogenous GABA (Pin and Bockaert, 1989). Weiss (1988a) and Pin and Bockaert (1989) also showed that Na^+ was clearly essential for this release to occur, and that the Ca^{2+} -independent/ Na^+ -dependent release was due to reversal of the GABA transporter. Normally, GABA influx through the transporter is driven by inward electrogenic Na^+ and Cl^- gradients: 2 Na^+ and 1 Cl^- per molecule of GABA. When large amounts of Na^+ accumulate in the neuronal cytoplasm from Glu receptor activation, the transporter is reversed to pump Na^+ and Cl^- out, as well as GABA which travels with the electrogenic gradient (Pin and Bockaert, 1989). The two types of GABA release, Ca^{2+} -dependent and -independent, are shown below in figure 27.

Ca^{2+} -dependent release results in exocytosis from vesicular stores, while Ca^{2+} -independent release results from cytoplasmic pools of GABA released through reversal of the transporter. It is likely, although not fully shown, that Glu evoked Ca^{2+} -independent release of GABA in this culture preparation was through depolarization-evoked reversal of the GABA transporter.




FIGURE 27 - Schematic representation of 2 major types of GABA release. Type 1 is calcium-dependent release from vesicles evoked by elevated KCl or 4-AP. Type 2 is independent of calcium, stimulated by Glu or other EAAs and mediated through reversal of the transporter. Adapted from Pin and Bockaert, 1989.

2. Dopamine receptor stimulation of GABA release

The D₁ DA receptor agonist, 6-Br-APB, stimulated the release of GABA to levels nearly 2-fold above basal release. While the lowest concentration tested, 3 nM, yielded no effect, both 30 and 60 nM were equally effective at evoking GABA release. A maximum effect was achieved by 30 nM, so further experiments were conducted to verify statistical significance ($P<0.01$) at this concentration. It seems likely that 30 nM 6-Br-APB is an ideal concentration to reach a stimulatory influence on GABA release, because its K_i for D₁ DA receptors is 1.37 nM (based on an IC₅₀ of 4.3 nM; Neumeyer et al., 1992), and applying concentrations higher than 60 nM may have approached the lower levels at which D₂ DA receptors would have been activated by the agonist. The D₁ receptor antagonist, SCH 23390 (30 nM), effectively blocked the agonist's stimulatory actions on GABA release ($P<0.005$) suggesting that 6-Br-APB stimulation of GABA release was purely receptor mediated. This was likely a direct effect on GABA release because of the DA receptor localization on GABA neurons in the striatum (Gerfen, 1992), and the proposed *in vivo* role of DA on striatonigral/endopeduncular efferents of the striatum (Gerfen, 1992; and Di Chiara and Morelli, 1993).

6-Br-APB increased potassium (50 mM KCl) stimulated release of GABA by 22 \pm 8%, yet failed to reach statistical significance ($P<0.01$); GABA release by 4-AP was not affected by the agonist. A possible reason that D₁ receptor stimulation did not significantly increase depolarization-evoked GABA release, is that potassium-stimulation and D₁ DA receptor activation increase release by similar mechanisms. Stimulation of D₁ DA receptors activates adenylyl cyclase (Anderson and Jansen, 1990) which ultimately stimulates internal Ca²⁺ accumulation; however, under depolarization, internal Ca²⁺ accumulation has already been activated, and therefore D₁ receptor stimulation of adenylyl cyclase would have no potentiating effect. The effects of elevating intracellular Ca²⁺ on DA receptor function must also be considered. Neuronal adenylyl cyclase is activated by Ca²⁺ when Ca²⁺ is bound to calmodulin (Ross, 1990), and this may desensitize D₁ DA receptors.

The inhibitory D₂ DA receptor agonist, quinelorane (30 and 100 nM), had no significant effects on either 30 or 50 mM KCl stimulated release of GABA. 30 mM KCl was used after studies were first conducted with the higher concentration of KCl; I thought that inhibitory effects on release could be better analyzed under a smaller depolarizing stimulus. Stimulation of D₂ DA receptors results in inhibition of adenylyl cyclase, modulation of phosphoinositide metabolism, enhancement of potassium conductance and inhibition of Ca²⁺ entry through voltage-sensitive Ca²⁺ channels (Cooper et al., 1996). These activities combined may not elicit an effect great enough to achieve a measurable reduction in the potassium evoked release of GABA from the cultured neurons. Also, elevated potassium may impose such a large change in the ion conductance across the GABA neurons that no inhibitory effects were likely to be observed through D₂ receptor activation.

3. GABA and μ -opiate receptor activity on stimulated release of GABA

GABA release evoked by either 50 mM KCl or 0.3 mM 4-AP was not affected by the μ -opiate receptor agonist, DAMGO at 1 μ M. Pharmacological evidence by Chneiweiss et al (1988) and Eriksson et al (1991) has shown that morphine and DAMGO inhibited adenylyl cyclase activity in fetal mouse striatal cultures which is suggestive of functional μ -opiate receptor activity in primary striatal cultures. The lack of DAMGO effects on stimulated GABA release in my experiments, may suggest that inhibitory actions of μ -opiate receptor stimulation are ineffective against powerful depolarizing agents such as potassium and 4-AP. As seen with quinelorane, the D₂ DA agonist, the depolarizing stimuli may alter the ion conductance of GABA neurons to a degree that cannot be affected by opiate receptor stimulation.

It is also possible that the released GABA might have been acting on striatal GABA receptors and thus be reducing the amount of GABA released by neuron depolarization. This might have masked any inhibitory effect of DAMGO. GABA receptor antagonists were added with the elevated potassium to determine if a significant amount GABA release

was being reduced by GABA receptor stimulation. Of the three antagonists tested only bicuculline, the GABA_A receptor antagonist, was effective at significantly increasing the 50 mM KCl stimulated release of GABA. It appeared that GABA was released and acting on GABA_A receptors to reduce its own release. A role for GABA_B receptors is less likely, since neither saclofen nor 2-OH saclofen caused significant changes in GABA release. Kowalski et al (1995) have shown that in fetal rat primary striatal cultures, most of the spontaneous synaptic inputs of striatal neurons were mediated by GABA, and that these GABA-induced currents were through Cl⁻ channels and sensitive to bicuculline. This GABA mediated effect was insensitive to GABA_B receptor antagonism and suggestive of GABA_A receptor activity (Kowalski et al., 1995). It is possible that GABA_B autoreceptor regulation of GABA release does not occur in the striatum, because as stated in the *Introduction*, GABA_B receptors are thought not to be expressed on either the terminals of recurrent collaterals or on the GABA cell bodies in the striatum (Seabrook et al., 1991). Instead, in this striatal culture preparation, I showed autoreceptor regulation of GABA release to occur through GABA_A receptors.

I was unable to show that DAMGO could completely block the bicuculline increase in potassium stimulated release of GABA. In six separate experiments, 100 μ M bicuculline increased stimulated release to $143 \pm 18\%$ control release ($P < 0.05$) and 1 μ M DAMGO, in five experiments, reduced this effect to $107 \pm 15\%$. Although an inhibitory trend appeared to occur, no statistical significance was established ($P > 0.05$). It is possible that a weak inhibitory effect of μ -opiate receptor activation is masked by the variance in this assay system.

CONCLUSIONS

The work I have presented focused on the regulation of Glu and GABA release from rat CP tissue slices and GABA release from primary cultures of fetal rat striatal neurons. Several aspects of this project I believe are significant in the advancement of pharmacology and neuroscience research, all of which stem from the methods I employed to analyze tissue releasate levels of the amino acids and the results I obtained from the release experiments.

I have described an improved method of measuring tissue levels of Glu and GABA through LCED analysis of OPA-SO₃ derivatized amino acids. This method was initially used to measure amino acid release from tissue slices using an unique 96-well microtiter plate release assay. The methodology was recently published (Phillips and Cox, 1997) and has received interest from the Millipore Corporation for its use with their Multiscreen microtiter plate and filtration system. Glu and GABA release from CP tissue slices induced by potassium depolarization, and GABA release induced by 4-AP were shown to be Ca²⁺-dependent, while the selective stimulation of Glu release by NMDA was not dependent on external Ca²⁺. Release studies with selective Ca²⁺ channel antagonists showed that Ca²⁺ influx through the P-type Ca²⁺ channel was required of Ca²⁺-dependent release, while Ca²⁺ influx through L- and N- type channels was not required of release. Surprisingly, ACh, DA and opiate receptor agonists failed to elicit effects on the release of Glu and GABA from the tissue slices. Primary striatal cultures (PSC) were employed as a more specific means of studying *in vitro* GABA release.

GABA release from PSC was evoked by potassium, 4-AP and Glu. Like NMDA stimulation of Glu release from the tissue slices, GABA release from the cultures evoked by Glu was independent of external Ca²⁺. I have proposed that EAA-receptor stimulated release of the amino acids under these experimental conditions is mediated through transporter reversal and most likely requires internal Na⁺ accumulation with a resulting

reversal of the ionic gradient driving the amino acid transport. The release of GABA by D₁ DA receptor stimulation was significant in showing that DA exerts a stimulatory influence on striatal GABA neurons in culture, as has been proposed for *in vivo* DA regulation of striatonigral/endopeduncular neurons. Also, the bicuculline stimulated increase in potassium-evoked GABA release was important in confirming that autoreceptor regulation of GABA release in the striatum occurs through GABA_A receptors and not the GABA_B receptor, under these experimental conditions.

The results reported here may also lead to further investigations into the regulation of *in vitro* GABA release. In particular, because specific opiate receptors are co-localized with D₁ DA receptors on striatal GABAergic neurons, the functional role of their co-localization could be measured by testing if opiate receptor stimulation could decrease the GABA release evoked by D₁ DA receptor activation.

REFERENCES

Abou-Khalil B, AB Young and JB Penney, Evidence for the pre-synaptic localization of opiate binding sites on striatal efferent fibers. *Brain Res*, 323 (1984), 21-29.

Albin RL, AM Young and JB Penney, The functional anatomy of basal ganglia disorders. *TINS*, 12 (1989), 366-75.

Albuquerque EX, JW Daly and JE Warnick, Macromolecular sites for specific neurotoxins and drugs on chemosensitive synapses and electrical excitation in biological membranes. In *Ion Channels*, T Narahashi ed., Plenum press, 1 (1988), 95-162.

Anderson PH and JA Jansen, Dopamine receptor agonists: selectivity and dopamine D₁ receptor efficacy. *Eur J Pharmacol*, 188 (1990), 335-47.

Anderson RA and R Mitchell, Evidence for GABA_B autoreceptors in median eminence. *Eur J Pharmacol*, 118 (1985), 355-8.

Arenas E, K Alberch, E Perez-Navarro, C Solsona and J Marsal, Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum. *J Neurosci*, 11 (1991), 2332-8.

Baruch P, F Artaud, G Godeheu, L Barbeito, J Glowinski and A Chéramy, Substance P and Neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons. *Neurosci*, 25 (1988), 889-98.

Bernard V, B Dumartin, E Lamy and B Bloch, Fos immunoreactivity after stimulation or inhibition of muscarinic receptors indicates anatomical specificity for cholinergic control of striatal efferent neurons and cortical neurons in the rat. *Eur J Neurosci*, 5 (1993), 1218-25.

Bernard V, E Normand and B Bloch, Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. *J Neurosci*, 12 (1992), 3591-600.

Bernath S and MJ Zigmond, Calcium-independent release from rat striatal slices: the role of calcium channels. *Neurosci*, 36 (1990), 677-82.

Bernath S, Calcium-independent release of amino acid neurotransmitters: fact or artifact? *Prog Neurobiol*, 38 (1992), 57-91.

Bolam JP, CA Ingham, PN Izzo, AI Levey, DB Rye, AD Smith and BH Wainer, Substance P-containing terminals in synaptic contact with cholinergic neurons in the neostriatum and basal forebrain: a double immunocytochemical study in the rat. *Brain Res*, 397 (1986), 279-89.

Bridges RJ, MS Stanley, MW Anderson, CW Cotman and AR Chamberlin, Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one-pyrrolidine-2,4-dicarboxylate diastereomer. *J Med Chem*, 34 (1991), 717-25.

Brewer GJ, JR Torricelli, EK Evege and PJ Price, Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. *J Neurosci Meth*, 35 (1993), 567-76.

Burke SP, ME Adams and CP Taylor, Inhibition of endogenous glutamate release from hippocampal tissue by Ca^{2+} channel toxins. *Eur J Pharmacol*, 238 (1993), 383-6.

Butcher SP, JW Lazarewicz and A Hamberger, *In vivo* microdialysis studies on the effects of decortication and excitotoxic lesions on kainic acid-induced calcium fluxes, and endogenous amino acid release, in the rat striatum. *J Neurochem*, 49 (1987), 1355-60.

Carpenter MB, Olfactory pathways, hippocampal formation, and the amygdala, In *Core Text of Neuroanatomy*. MB Carpenter ed., Williams and Wilkens, 4 (1991), 361-89.

Carvalho CM, SV Santos, and AP Carvalho, γ -Aminobutyric acid release from synaptosomes as influenced by Ca^{2+} and Ca^{2+} channel blockers. *Eur J Pharmacol*, 131 (1986), 1-12.

Cedarbaum JM and LS Schleifer, Drugs for Parkinson's Disease, spasticity, and acute muscle spasms. In *Goodman and Gillman's The Pharmacological Basis of Therapeutics*, AG Gillman, TW Rall, AS Nies and P Taylor eds., Pergamon Press, 8 (1990), 463-84.

Cepeda C, NA Buchwald and MS Levine, Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. *Neurobiol*, 90 (1993), 9576-80.

Chang HT, Dopamine-acetylcholine interaction in the rat striatum: a dual-labeling immunocytochemical study. *Brain Res Bull*, 21 (1988), 295-304.

Chittajallu R, M Vignes, KK Dev, JM Barnes, GL Collingridge and JM Henley, Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. *Nature*, 379 (1996), 78-81.

Chneiweiss H, J Glowinski and J Premont, Mu and delta opiate receptors coupled negatively to adenylate cyclase on embryonic neurons from the mouse striatum in primary cultures. *J Neurosci*, 8 (1988), 3376-88.

Cooper JR, FE Bloom, and RH Roth, *The Biochemical Basis of Neuropharmacology*. Oxford University Press, Oxford, 6 (1991), 133-89.

Cooper JR, FE Bloom, and RH Roth, *The Biochemical Basis of Neuropharmacology*. Oxford University Press, Oxford, 7 (1996), 293-351.

Danks JA, RB Rothman, MA Cascieri, GG Chicchi, T Liang and M Herkenham, A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. *Brain Res*, 385 (1986), 273-81.

Del Río J, JR Naranjo, H-YT Yang and E Costa, Substance P-induced release of met5-enkephalin from striatal and periaqueductal gray slices. *Brain Res*, 279 (1983), 121-6.

Dewer D, P Jenner and CD Marsden, Effects of opioid agonist drugs on the *in vitro* release of [^3H]-GABA, [^3H]-dopamine, and [^3H]-5-HT from slices of rat globus pallidus. *Biochem Pharmacol*, 36 (1987), 1738-41.

Di Chiara G and M Morelli, Dopamine-acetylcholine-glutamate interactions in the striatum, a working hypothesis. *Adv Neurol*, 60 (1993), 102-6.

Di Chiara G, M Morelli and S Consolo, Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. *TINS*, 17 (1994), 228-33.

Donzanti BA and BK Yamamoto, An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue and microdialysis perfusates. *Life Sci.*, 43 (1988), 913-22.

Ennis C, JD Kemp and B Cox, Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. *J Neurochem.*, 36 (1981), 1515-20.

Eriksson PS, E Hansson and L Ronnback, Mu and delta opiate receptors in neuronal and astroglial primary cultures from various regions of the brain--coupling with adenylate cyclase, localisation on the same neurones and association with dopamine (D₁) receptor adenylate cyclase. *Neuropharmacol.*, 30 (1991), 1233-9.

Errington ML, MA Lynch and TVP Bliss, Long term potentiation in the dentate gyrus: Induction and increased glutamate release are blocked by D-(-)aminophosphonovalerate. *Neurosci.*, 20 (1987), 279-84.

Fagg GE and A Matus, Selective association of N-methyl aspartate and quisqualate types of L-glutamate receptor with brain postsynaptic densities. *Proc Natl Acad Sci.*, 81 (1984), 6876-80.

Fallgren AB and RE Paulsen, A microdialysis study in rat brain of dihydrokainate, a glutamate uptake inhibitor. *Neurochem Res.*, 21 (1996), 19-25.

Fonnum F, I Walaas and E Iverson, Localization of GABAergic, cholinergic and aminergic structures in the mesolimbic system. *J Neurochem.*, 29 (1977), 221-30.

Fuxe K, LF Agnati, M Kalia, M Goldstein, K Andersson and A Härfstrand, Dopaminergic systems in the brain and pituitary. In *Basic and Clinical Aspects of Neuroscience*. E Flückiger, EE Müller and MO Thorner eds., Springer Sandoz, (1985), 11-25.

Gerfen CR, Substance P (neurokinin-1) receptor mRNA selectively expressed in cholinergic neurons in the striatum and basal forebrain. *Brain Res.*, 556 (1991), 165-70.

Gerfen CR, The neostriatal mosaic: multiple levels of compartmental organization. *TINS*, 15 (1992), 133-39.

Glowinski J, C Gauchy, M-O Krebs, L Tremblay, M Desban and M-L Kemel, Presynaptic regulation of dopamine release in striatal compartments and functional heterogeneity of the matrix. In *The Basal Ganglia IV*, G Percheron, JS McKenzie and J Féger eds., Plenum Press, (1994), 411-9.

Graybiel AM, Neurotransmitters and neuromodulators in the basal ganglia, *TINS*, 13 (1990), 244-254.

Graybiel AM, RW Baughman and F Eckenstein, Cholinergic neuropil of the striatum observes striosomal boundaries. *Nature*, 323 (1986), 625-7.

Graybiel AM, T Aosaki, AW Flaherty and M Kimura, The Basal Ganglia and Adaptive Motor Control, *Science*, 265 (1993), 1826-31.

Greenamyre JT and AB Young, Synaptic localization of striatal NMDA, quisqualate, and kainate receptors. *Neurosci Lett*, 101 (1989), 133-7.

Groenewegen HJ, HW Berendse and FG Wouterlood, Organization of the projections from the ventral striato-pallidal system to ventral mesencephalic dopaminergic neurons in the rat. In *The Basal Ganglia IV*, G Percheron, JS McKenzie and J Féger eds., Plenum Press, (1994), 81-93.

Guttman M, Receptors in the basal ganglia. *Can J Neurol Sci*, 14 (1987), 395-401.

Haber SN and WJH Nauta, Ramifications of the globus pallidus in the rat as indicated by patterns of immunohistochemistry. *Neurosci*, 9 (1983), 245-60.

Heijna MH, F Hogenboom, AH Mulder and ANM Schoffelmeer, Opioid receptor-mediated inhibition of [³H]-dopamine and [¹⁴C]-acetylcholine release from rat nucleus accumbens slices. *Naunyn-Schmeid Arch Pharmacol*, 345 (1992), 627-32.

Heimer L, J de Olmos, GF Alheid and L Záborszky, "Perestroika" in the basal forebrain: Opening the border between neurology and psychiatry. In *Progress in Brain Research*, G Holstege ed., Elsevier Science, 87 (1991), 109-65.

Hell JW, RE Westenbroek, C Warner, MK Ahlijanian, W Prystay, MM Gilbert, TP Snutch and WA Catterall, Identification and differential subcellular localization of the neuronal class C and class D L-type calcium channel $\alpha 1$ subunits. *J Cell Biol*, 123 (1993), 949-62.

Herdon H, J Strupish and SR Nahorski, Differences between the release of radiolabelled and endogenous dopamine from superfused rat brain slices: Effects of depolarizing stimuli, amphetamine and synthesis inhibition. *Brain Res*, 348 (1985), 309-20.

Hill DR and HG Bowery, [³H]-Baclofen and [³H]-GABA bind to bicuculline-insensitive GABA_B sites in rat brain. *Nature*, 290 (1981), 149-52.

Hillman D, S Chen, TT Aung, B Cherksey, M Sugimori and RR Llinás, Localization of P-type calcium channels in the central nervous system. *Proc Natl Acad Sci USA*, 88 (1991), 7076-80.

Hoyt KR and JJ Reynolds, Localization of D₁ dopamine receptors on live cultured striatal neurons by quantitative fluorescence microscopy. *Brain Res*, 731 (1996), 21-30.

Hu P-S and BB Fredholm, 4-Aminopyridine-induced increases in basal and stimulation-evoked [³H]-NA release in slices from rat hippocampus: Ca^{2+} sensitivity and presynaptic control. *Br J Pharmacol*, 102 (1991), 764-8.

Izzo PN and JP Bolam, Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat. *J Comp Neurol*, 269 (1988), 219-34.

Jacobs WA, o-Phthalaldehyde-sulfite derivatization of primary amines for liquid chromatography-electrochemistry. *J Chromatography*, 392 (1987), 435-41.

Jacocks HM and BM Cox, Serotonin-stimulated release of [³H]-dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: a comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. *J Pharmacol Exp Ther*, 262 (1992), 356-64.

Jiang ZG and RA North, Pre- and postsynaptic inhibition by opioids in rat striatum. *J Neurosci*, 12 (1992), 356-61.

Johnston GAR, AL Stephanson and B Twitchin, Uptake and release of nipecotic acid by rat brain slices. *J Neurochem*, 26 (1976), 83-7.

Johnston GAR, SME Kennedy and B Twitchin, Action of the neurotoxin kainic acid on high affinity uptake of L-glutamic acid in rat brain slices. *J Neurochem*, 32 (1979), 121-7.

Jolkonen J, M Mazurkiewicz, H Lahtinen and P Riekkinen, Acute effects of γ -vinyl GABA on the GABAergic system in rats as studied by microdialysis. *Eur J Pharm*, 229 (1992), 269-72.

Joseph MH and P Davies, Application to high-performance liquid chromatographic determination of amino acids in plasma and other biological materials. *J Chromatography*, 277 (1983), 125-36.

Jouanen A, A-M Tremblet, D Massardier, J-L Haesslein and PF Hunt, GABA release from mouse striatal neurons in primary culture as a test for the functional activity of N-methyl-D-aspartate (NMDA) antagonists. *J Neurosci Meth*, 36 (1991), 27-32.

Julius D, Molecular biology of serotonin receptors. *Ann Rev Neuroscience*, 14 (1991), 335-60.

Kanai Y, M Stelzner, S Nubberger, S Khawaja, SC Hebert, CP Smith and MA Hediger, The neuronal and epithelial human high affinity glutamate transporter. *J Biol Chem*, 269 (1994), 20599-606.

Kandel ER and JH Schwartz, Directly gated transmission at central synapses. In *Principles of Neural Science*, ER Kandel, JH Schwartz and TM Jessell eds., Elsevier Science Publishing Co., 3 (1991), 153-212.

Kandel ER, Transmitter release. In *Principles of Neural Science*, ER Kandel, JH Schwartz and TM Jessell eds., Elsevier Science Publishing Co., 3 (1991), 194-212.

Kemp JM and TP Powell, The cortico-striate projection in the monkey. *Brain*, 93 (1970), 525-46.

Kim K-W and BM Cox, Inhibition of norepinephrine release from rat cortex slices by opioids: differences among agonists in sensitivities to antagonists suggest receptor heterogeneity. *J Pharmacol Exp Ther*, 267 (1993), 1153-60.

Kimura M, Y Yamanishi, T Hanada, T Kagaya, M Kuwada, T Watanabe, K Katayama and Y Nishizawa, Involvement of P-type calcium channels in high potassium-elicited release of neurotransmitters from rat brain slices. *Neurosci*, 66 (1995), 609-15.

Kötter R, Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. *Prog Neurobiol*, 44 (1994), 163-96.

Kowalski C and P Giraud, Dopamine decreases striatal enkephalin turnover and proenkephalin messenger RNA abundance via D₂ receptor activation in primary striatal cell cultures. *Neurosci*, 53 (1993), 665-72.

Kowalski C, M Crest, J Vuillet, T Pin, M Gola and A Nieoullon, Emergence of a synaptic neuronal network within primary striatal cultures seeded in serum-free medium. *Neurosci*, 64 (1995), 979-93.

Kubota Y, S Inagaki, S Shimada, S Kito, F Eckenstein and M Tohyama, Neostriatal cholinergic neurons receive direct synaptic inputs from dopaminergic axons. *Brain Res*, 413 (1987), 179-84.

Lapchak PA, DM Araujo and B Collier, Regulation of endogenous acetylcholine release from mammalian brain slices by opiate receptors: hippocampus, striatum and cerebral cortex of guinea pig and rat. *Neurosci*, 31 (1989), 313-25.

Lapper SR and JP Bolam, Input from the frontal cortex and the papafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. *Neurosci*, 51 (1992), 533-45.

Larsson OM, E Falch, P Krogsgaard-Larsen and A Schousboe, Kinetic characterization of inhibition of gamma-aminobutyric acid uptake into cultured neurons and astrocytes by 4,4-diphenyl-3-butenyl derivatives of nipecotic acid and guvacine. *J Neurochem*, 50 (1988), 818-23.

Lecharny J-B, F Salord, D Henzel, J-M Desmonts and J Mantz, Effects of thiopental, halothane and isoflurane on the calcium-dependent and -independent release of GABA from striatal synaptosomes in the rat. *Brain Res*, 670 (1995), 308-12.

Lindroth P and K Mopper, High performance liquid chromatographic determination of subpicomole amounts of amino acids by pre-column fluorescence derivatisation with o-phthaldialdehyde. *Anal Chem*, 51 (1979), 1667-74.

Lippert B, BW Metcalf, MJ Jung and P Casara, 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. *Eur J Biochem*, 74 (1977), 441-45.

Loscher W, Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA. *J Neurochem*, 34 (1980), 1603-8.

Lovoie B and A Parent, Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. *J Comp Neurol*, 299 (1990), 1-16.

Maneuf YP, IJ Mitchell and AR Crossman, Enkephalin-GABA co-transmission in the striatopallidal pathway in parkinsonism. In *The Basal Ganglia IV*, G Percheron, JS McKenzie and J Féger eds., Plenum Press, (1994), 449-55.

Mansour A, CA Fox, H Akil and SJ Watson, Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. *TINS*, 18 (1995), 22-29.

Maus M, P Vernier, O Valdenaire, V Homburger, J Bockaert, J Glowinski and J Mallet, D₂ dopaminergic agonist quinpirole and 8-bromo-cAMP have opposite effects on G_o alpha GTP-binding protein mRNA without changing D₂ dopamine receptor mRNA levels in striatal neurones in primary culture. *J Recept Res*, 13 (1993), 313-28.

McDowell J and I Kitchen, Development of opioid systems: peptides, receptors and pharmacology. *Brain Res Rev*, 12 (1987), 397-421.

McDowell J and I Kitchen, Ontogenesis of delta-opioid receptors in rat brain using [3 H][D-Pen₂,D-Pen₅]enkephaline as a binding ligand. *Eur J Pharmacol.*, 128 (1986), 287-9.

Meredith GE and FG Wouterlood, Hippocampal and midline thalamic fibers and terminals in relation to the choline acetyltransferase-immunoreactive neurons in nucleus accumbens of the rat: a light and electron microscopic study. *J Comp Neurol.*, 296 (1990), 204-21.

Mulder AH, G Wardeh, F Hogenboom and AL Frankhuyzen, Kappa and delta opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. *Nature*, 308 (1984), 278-80.

Neumeyer JL, NS Kula, RJ Baldessarini and N Baird, Stereoisomeric probes for the D₁ dopamine receptor: Synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue. *J Med Chem.*, 35 (1992), 1466-74.

Nicholls DG and TS Sihra, Synaptosomes possess an exocytotic pool of glutamate. *Nature*, 321 (1986), 772-3.

Noble F and BM Cox, Differential regulation of D₁ dopamine receptor- and of A_{2a} adenosine receptor-stimulated adenylyl cyclase by μ -, δ_1 -, and δ_2 -opioid agonists in rat caudate putamen. *J Neurochem.*, 65 (1995), 125-33.

Norris PJ, DK Dhaliwal, DP Druce and HF Bradford, The suppression of stimulus-evoked release of amino acid neurotransmitters from synaptosomes by verapamil. *J Neurochem.*, 40 (1983), 514-21.

North RA, Opioid receptor types and membrane ion channels. *TINS*, 9 (1986), 114-17.

Ohta K, Y Fukuuchi, K Shimazu, S Komatsu, M Ichijo, N Araki and M Shibata, Presynaptic glutamate receptors facilitate release of norepinephrine and 5-hydroxytryptamine as well as dopamine in the normal and ischemic striatum. *J Autonomic Nerv System*, 49 (1994), S195-S202.

Olferman HJ, AW Jones, KN Mewett and JC Watkins, Structure/activity relations of N-methyl-D-aspartate receptor ligands as studied by their inhibition of [3 H]-D-2-amino-5-phosphonopentanoic acid binding in rat brain membranes. *Neurosci*, 26 (1988), 17-31.

Palacios JM and MM Dietl, Autoradiographic studies of serotonin receptors. In *The Serotonin Receptors*, E Sanders-Bush ed., The Humana Press, (1988), 89-348.

Pearson SJ, C Czudek, K Mercer and GP Reynolds, Electrochemical detection of human brain transmitter amino acids by high-performance liquid chromatography of stable o-phthalaldehyde-sulphite derivatives. *J Neural Transm*, 86 (1991), 151-57.

Peterson GL, A simplification of the protein assay method of Lowry et al which is more generally applicable. *Analytical Biochem*, 83 (1977), 346-56.

Phillips JB and BM Cox, Release of endogenous glutamate and γ -aminobutyric acid from rat striatal tissue slices measured by an improved method of high performance liquid chromatography with electrochemical detection. *J Neurosci Meth*, in press (1997).

Pin J-P and J Bockaert, Multiple voltage-sensitive calcium channels are probably involved in endogenous GABA release from striatal neurons differentiated in primary culture. *Naunyn-Schmeid Arch Pharmacol*, 336 (1987), 190-6.

Pin J-P and J Bockaert, Two distinct mechanisms, differentially affected by excitatory amino acids, trigger GABA release from fetal mouse striatal neurons in primary culture. *J Neurosci*, 9 (1989), 648-56.

Pin JP, BJ Van-Vliet and J Bockaert, Complex interaction between quisqualate and kainate receptors as revealed by measurement of GABA release from striatal neurons in primary cultures. *Eur J Pharmacol*, 172 (1989), 81-91.

Pin JP, BJ Van-Vliet and J Bockaert, NMDA- and kainate- evoked GABA release from striatal neurons differentiated in primary culture: differential blocking by phencyclidine. *Neurosci Lett*, 87 (1988), 87-92.

Reynolds GP and SJ Pearson, Measurement of γ -aminobutyric acid and glutamate in brain tissue. In *High Performance Liquid Chromatography in Neuroscience Research*, RB Holman, AJ Cross and MH Joseph eds., John Wiley and Sons, England, 15 (1993), 101-17.

Riederer P, KW Lange, J Kormhuber and W Danielczyk, Glutamatergic-dopaminergic balance in the brain. *Arzneim-Forsch/Drug Res*, 42 (1992), 265-68.

Robinson MB, M Hunter-Ensor and J Sinor, Pharmacologically distinct sodium-dependent L-[3 H]-glutamate transport processes in rat brain. *Brain Res*, 544 (1991), 196-202.

Ross EM, Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect. In *The Pharmacological Basis of Therapeutics*, AF Gilman, TW Rall, AS Nies and P Taylor eds., Pergamon Press, New York, 11 (1990), 33-48.

Rowley HL, KF Martin and CA Marsden, Determination of *in vivo* amino acid neurotransmitters by high-performance liquid chromatography with o-phthalaldehyde-sulphite derivatisation. *J Neurosci Meth*, 57 (1995), 93-9.

Sandor NT, B Lendvai and ES Vizi, Effect of selective opiate antagonists on striatal acetylcholine and dopamine release. *Brain Res Bull*, 29 (1992), 369-73.

Schoffelmeer ANM, TJ de Vries, F Hogenboom, VJ Hruby, PS Portoghese and AH Mulder, Opioid receptor antagonists discriminate between presynaptic mu and delta receptors and the adenylate cyclase-coupled opioid receptor complex in the brain. *J Pharmacol Exp Ther*, 263 (1992), 20-24.

Schousboe A, P Thorbek, L Hertz and P Krogsgaard-Larsen, Effects of GABA analogues of restricted conformation on GABA transport in astrocytes and brain cortex slices and on GABA receptor binding. *J Neurochem*, 33 (1979), 181-9.

Seabrook GR, W Howson and MG Lacey, Subpopulations of GABA-mediated synaptic potentials in slices of rat dorsal striatum are differentially modulated by presynaptic GABA_B receptors. *Brain Res*, 562 (1991), 332-4.

Self DW and EJ Nestler, Molecular mechanisms of drug reinforcement and addiction. *Annual Rev Neuroscience*, 18 (1995), 463-95.

Semba K, HC Fibiger and SR Vincent, Neurotransmitters in the mammalian striatum: neuronal circuits and heterogeneity. *Can J Neurol Sci*, 14 (1987) 386-94.

Simmons ML, GW Terman, SM Gibbs and C Chavkin, L-type calcium channels mediate dynorphin neuropeptide release from dendrites but not axons of hippocampal granule cells. *Neuron*, 14 (1995), 1265-72.

Smith AD and JP Bolam, The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. *TINS*, 13 (1990), 259-65.

Smith S and T Sharp, Measurement of GABA in rat brain microdialysates using o-phthalodialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. *J Chromatography*, 652 (1994a), 228-33.

Smith SE and T Sharp, An investigation of the origin of extracellular GABA in rat nucleus accumbens measured *in vivo* by microdialysis. *J Neural Transm*, 97 (1994b), 161-71.

Smith Y and A Parent, Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. *Brain Res*, 453 (1988), 353-6.

Smith Y, T Wichmann and MR DeLong, The external pallidum and the subthalamic nucleus send convergent synaptic inputs onto single neurons in the internal pallidal segment in monkey: anatomical organization and functional significance. In *The Basal Ganglia IV*, G Percheron, JS McKenzie and J Féger eds., Plenum Press, (1994), 51-62.

Soghomoniam JJ, L Descarries and KC Watkins, Serotonin innervation in adult rat neostriatum II, Ultrastructural features: A radioautographic and immunocytochemical study. *Brain Res*, 86 (1989), 481-67.

Steinbusch HWM, Serotonin-immunoreactive neurons and their projections in the CNS. In *Classical Transmitters and Transmitter Receptors in the CNS Part II*, A Björklund, T Hökfelt and MJ Kuhar eds., 3 (1984), 68-125.

Stoof JC, B Drukarch, P de Boer and BHC Westerink, *In vitro* and *in vivo* acetylcholine release from rat striatum as a functional paradigm of signal transduction via a D-2 dopamine receptor. *Neurochem Int*, 20 suppl (1992), 201S-205S.

Takahashi T and A Momiyama, Different types of calcium channels mediate central synaptic transmission. *Nature*, 366 (1993), 156-8.

Thesleff S, Aminopyridines and synaptic transmission. *Neurosci*, 5 (1980), 1413-9.

Turner TJ, ME Adams and K Dunlap, Multiple Ca^{2+} channel types coexist to regulate synaptosomal neurotransmitter release. *Proc Natl Acad Sci USA*, 90 (1993), 9518-22.

Van Bockstaele EJ and VM Pickel, GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. *Brain Res*, 682 (1995), 215-21.

Voet D and JG Voet, Amino acid metabolism. In *Biochemistry*, D Voet and JG Voet eds., John Wiley and Sons, England, 1 (1990), 678-729.

Waeber C and JM Palacios, Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the basal ganglia. *Molecular Brain Res*, 24 (1994), 199-209.

Waldmeier PC and PA Baumann, Presynaptic GABA receptors. *Ann NY Acad Sci*, 604 (1990), 136-51.

Waldmeier PC, K Stöcklin and JJ Feldtrauer, Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum. *Naunyn-Schmeid Arch Pharm*, 345 (1992), 544-7.

Waldmeier PC, P Wicki and JJ Feldtrauer, Release of endogenous glutamate from rat cortical slices in presence of the glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid. *Naunyn-Schmeid Arch Pharmacol*, 348 (1993), 478-85.

Waldmeier PC, P Wicki, JJ Feldtrauer and PA Baumann, Potential involvement of a baclofen-sensitive autoreceptor in the modulation of the release of endogenous GABA from rat brain slices *in vitro*. *Naunyn-Schmeid Arch Pharm*, 337 (1988), 289-95.

Waldmeier PC, P Wicki, JJ Feldtrauer and PA Baumann, Release of endogenous GABA from the substantia nigra is not controlled by GABA autoreceptors. *Naunyn-Schmeid Arch Pharm*, 340 (1989), 372-8.

Weiss S, Excitatory amino acid-evoked release of GABA from striatal neurons in primary culture. *J Neurochem*, 51 (1988a), 435-41.

Weiss S, Forskolin attenuates the evoked release of [³H]-GABA from striatal neurons in primary culture. *Brain Res*, 463 (1988b), 182-6.

Weiss S, Pharmacological properties of the N-methyl-D-aspartate receptor system coupled to the evoked release of γ -[³H]-aminobutyric acid from striatal neurons in primary culture. *J Pharmacol Exp Ther*, 252 (1990), 380-6.





Werling LL, A Frattali, PS Portoghese, AE Takemori and BM Cox, Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. *J Pharmacol Exp Ther*, 246 (1988), 282-6.

Westenbroek RE, JW Hell, C Warner, SJ Dubel, TP Snutch and WA Catterall, Biochemical properties and subcellular distribution of an N-type calcium channel $\alpha 1$ subunit. *Neuron*, 9 (1992), 1099-115.

Young AMJ and HF Bradford, N-methyl-D-aspartate releases excitatory amino acids in rat corpus striatum *in vivo*. *J Neurochem*, 56 (1991), 1677-83.

Yunger LM, PJ Fowler, P Zarevics and PE Setler, Novel inhibitors of γ -aminobutyric acid (GABA) uptake: anticonvulsant actions in rats and mice. *J Pharmacol Exp Ther*, 228 (1984), 109-15.

IMAGE EVALUATION TEST TARGET (QA-3)



APPLIED IMAGE, Inc
1653 East Main Street
Rochester, NY 14609 USA
Phone: 716/482-0300
Fax: 716/288-5989

© 1993, Applied Image, Inc., All Rights Reserved

